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Abstract
Bispecific T cell engagers (BiTEs), artificial antibodies designed to cross-link T cells to tumor
cells, and chimeric antigen receptors (CARs), expressed on the surface of modified T cells and
transferring activating signals via intracellular domains, can re-direct T cells to tumor surface
antigens for efficient treatment of hematological malignancies. In solid tumors, however, these
novel immunotherapies face fundamental challenges: Physical exclusion of T cells and an immuno-
suppressive microenvironment prevent efficacy while systemic administration is associated with
severe toxicities. Oncolytic viruses have emerged as ideal agents for combination immunotherapies,
as lytic replication in tumors does not only induce tumor debulking, but also immunogenic cancer
cell death and local inflammation. We therefore hypothesized that oncolytic virotherapy, by
eliminating physical barriers and reversing local immunosuppression, can promote anti-tumor T
cell responses and thus provide a potent treatment option for solid tumors in combination with T
cell re-direction. We furthermore hypothesized that tumor-targeted expression of a virus-encoded
BiTE could achieve local BiTE activity without systemic side effects.
To test these hypotheses, we engineered oncolytic measles viruses (MV) encoding BiTEs targeting
CD20 or carcinoembryonic antigen, respectively, as model antigens (MV-BiTE). Kinetics of viral
replication and virus-mediated cytotoxicity showed minor differences compared to unmodified
virus, and functional BiTEs could be obtained from the supernatant of virus-infected cells.
A newly established syngeneic solid tumor model of B16-CD20-CD46 murine melanoma cells
stably expressing human antigens CD20 and CD46 as BiTE target antigen and measles virus
entry receptor, respectively, engrafted in immunocompetent C57BL/6 mice when implanted
subcutaneously. In this model, treatment with MV-BiTE targeting CD20 significantly prolonged
survival compared to control treatments with unmodified MV, MV encoding CEA-specific control
BiTE, purified BiTE, or carrier fluid only, respectively. UV irradiation of MV-BiTE completely
inhibited viral replication but did not abrogate efficacy in this model. Treatment efficacy was
furthermore not impaired in mice previously immunized with MV. Increased T cell infiltration
into tumors and an effector T cell phenotype characterized by high intratumoral CD8+ T cell
levels and low relative abundance of regulatory T cells was observed upon MV-BiTE treatment.
Targeted transcriptome analysis revealed upregulation of genes associated with T cell activation,
proliferation, and differentiation, but also with inhibition and exhaustion, providing a rationale
for combination with checkpoint inhibitors.
Combinations of MV, BiTE, and CAR T cell therapies were investigated in a pancreatic cancer
model. Cytotoxic potential of each treatment alone towards human pancreatic adenocarcinoma
cells was observed in vitro. However, no significant benefit of combinations was observed in a
pilot experiment in immunodeficient mice, and T cell persistence was limited. For future in vivo
monitoring of T cells by magnetic resonance imaging, labeling with iron oxide nanoparticles was
established. In addition, we describe a mathematical model for in silico predictions of treatment
outcome to optimize scheduling of combination therapies.
Taken together, this study shows for the first time efficacy of a BiTE-encoding oncolytic virus in an
immunocompetent mouse model. This warrants further investigations towards future translation.
We furthermore introduced a mathematical model of combination immunovirotherapy to further
support the development of novel treatment options for cancer patients.
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Zusammenfassung
Mithilfe von künstlichen bispezifischen Antikörpern (BiTEs) oder durch gentechnische Einführung
chimärer Rezeptoren (CARs) lassen sich T-Zellen auf Tumor-Oberflächenantigene umlenken. Diese
neuen Immuntherapien werden klinisch bereits zur Behandlung von hämatologischen Neoplasien
eingesetzt. Der therapeutische Nutzen von BiTE- oder CAR-T-Zell-Therapien über diese Entitäten
hinaus ist allerdings begrenzt, da die systemische Gabe mit schweren bis lebensbedrohlichen
Nebenwirkungen verbunden sein kann und solide Tumoren über physikalische Barrieren und im-
munsuppressive Mechanismen verfügen, die das Eindringen sowie die anti-tumorale Aktivität von
T-Zellen verhindern. Onkolytische Viren sind gekennzeichnet durch einen Tumorzell-spezifischen,
lytischen Replikationszyklus, was einerseits zu einer direkten Reduktion der Tumorlast und ander-
erseits zu einer lokalen Entzündungsreaktion führen kann, die eine anti-tumorale T-Zell-Antwort
begünstigt. Daraus leiten wir die Hypothese ab, dass die Kombination von Virotherapie mit
T-Zell-Umlenkung eine wirksame Behandlung von soliden Tumoren ermöglicht, was in dieser
Arbeit experimentell untersucht wurde. Wir vermuteten weiterhin, dass die gezielte Expression
von virus-kodierten BiTEs durch infizierte Tumorzellen eine starke, lokal begrenzte Umlenkung
von T-Zellen bei geringerer Toxizität gegenüber systemischer Applikation bewirken kann.
Um diese Hypothesen zu testen, entwickelten wir Masern-Impfstamm-Viren (MV), die in ihrem
Genom BiTEs kodieren, die entweder CD20 oder CEA, zwei Modell-Tumorantigene, erkennen
und T-Zellen darauf umlenken können (MV-BiTE). Diese Viruskonstrukte zeigten im Vergleich zu
unmodifizierten Impfviren nur geringe Unterschiede im Hinblick auf Replikationsgeschwindigkeit
und lytische Aktivität, und funktionelle BiTEs konnten aus dem Überstand virusinfizierter Zellen
isoliert werden. Eine neue Tumorzelllinie auf Basis der Maus-Melanom-Zelllinie B16, die zusät-
zlich die humanen Antigene CD20 als BiTE-Zielantigen und CD46 als Masernvirus-Rezeptor
auf der Zelloberfläche exprimiert, formte subkutane Tumoren in syngenen immunkompetenten
C57BL/6-Mäusen. In diesem Modell verlängerte die Tumorbehandlung mit CD20-spezifischen
MV-BiTE das Überleben von Mäusen signifikant im Vergleich zu unmodifizierten MV, zu Kon-
trollviren, die den CEA-spezifischen BiTE kodieren, zu aufgereinigten BiTEs, und zur Injektion
von Pufferlösung ohne Viren. Bestrahlung von MV-BiTE mit UV-Licht inhibierte effektiv die
Replikationsfähigkeit der Viren, führte aber nicht zur Unwirksamkeit der Behandlung. Außerdem
war die Behandlung auch in zuvor mit Masernviren immunisierten Tieren wirksam. Im Vergleich
zu Kontrollbehandlungen wiesen die mit MV-BiTE behandelten Tumoren eine erhöhte Infiltration
von T-Zellen sowie ein von zytotoxischen Effektorzellen geprägtes T-Zell-Profil mit wenigen
regulatorischen T-Zellen auf. Die Transkriptomanalyse von Tumorproben zeigte eine verstärkte
Expression von Genen, die mit der Aktivierung, Proliferation und Differenzierung, aber auch der
Inhibition und Erschöpfung von T-Zellen assoziiert sind. Dies bietet eine Rationale für zukünftige
Kombination von MV-BiTE mit Immuncheckpoint-Inhibitoren.
Kombinationen von CAR-T-Zell-, BiTE- und MV-Therapien wurden in einem Pankreastumor-
Modell untersucht. Alle untersuchten Kombinationen zeigten zytotoxisches Potential gegenüber
menschlichen Pankreas-Adenokarzinom-Zellen in vitro. In einem Pilotexperiment in immundefizien-
ten Mäusen wurde jedoch keine erhöhte Wirksamkeit der Therapiekombinationen nachgewiesen
und die Persistenz von transferierten humanen T-Zellen war limitiert. Um zukünftig trans-
ferierte T-Zellen in Mäusen über einen längeren Zeitraum hinweg mittels nichtinvasiver Magne-
tresonanztomographie visualisieren zu können, wurde ein Protokoll zur T-Zell-Markierung mit
II
Zusammenfassung
Eisenoxid-Nanopartikeln etabliert. Außerdem wurde im Rahmen dieser Arbeit ein mathema-
tisches Modell zur Simulation kombinierter Viro- und T-Zell-Immuntherapien erstellt, um die
Behandlungsplanung durch in silico-Experimente zu optimieren.
Zusammengefasst liegt hiermit erstmals eine Studie vor, die die Wirksamkeit von BiTE-kodierenden
onkolytischen Viren in einem immunkompetenten Modell nachweist. Diese Ergebnisse machen
weitere translationale Forschung nötig, um das Konzept auf seine klinische Anwendbarkeit hin zu
prüfen. Auch das entwickelte mathematische Modell kombinierter Immunovirotherapien kann zu
einer Entwicklung neuer Behandlungsoptionen für Krebspatienten beitragen.
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1 Introduction
1.1 Motivation
Despite significant scientific and clinical advances in the last century, cancer diseases remain
the second leading cause of death worldwide, with an estimated total of 9.6 million deaths in
2018 attributable to cancer according to the World Health Organization. While relative cancer
mortality is expected to decrease at least in the European Union, the total number of cancer
deaths is not declining, partly due to population ageing1. Thus, in addition to better prevention
and diagnostic procedures, improved treatment options are desperately needed.
1.2 Immunotherapy: A brief historical perspective
Therapies that are in clinical use since decades, including chemotherapy and radiotherapy, often
only reduce tumor burden while failing to prove truly curative potential2. Immunotherapeutic
approaches, i.e. therapies manipulating the patient’s own immune system to achieve detection
and elimination of cancerous structures, are now widely appreciated as a promising way to achieve
long-term tumor control. However, immunotherapy has long been regarded as an impossible or at
least impractical idea. First promising practical evidence has been brought about by William
Coley testing the application of heat-inactivated bacterial suspensions against cancer3, which has
been met with reluctance by the medical community, as was Paul Ehrlich’s theoretical concept
of tumor immunosurveillance4. In particular, a lacking understanding of the underlying biology
together with experimental setbacks had prevented large-scale clinical application for a long
time.
While a potential role of lymphocytes, in particular T cells, had been discussed in the context of
tumor control, a study in athymic nude mice showing no evidence of increased tumor incidence
compared to phenotypically normal heterozygotic mice challenged this hypothesis5. It was not
until several decades later that in a novel mouse model, which in contrast to athymic nude mice
completely lacked functional T cells, earlier tumor onset was observed, proving the importance of
T cells in tumor immunosurveillance6. This exemplifies the challenges the field has faced due
to insufficient theoretical and experimental knowledge, which had to be overcome by scientific
investigation. Following early clinical studies in the 1970s7, the BCG vaccine was introduced for
treatment of superficial bladder cancer as the first anti-cancer immunotherapeutic and continues
to be standard-of-care for this disease entity (reviewed in8). The efficacy of chemotherapeutic,
radiotherapeutic, and even more recently developed targeted approaches aiming at tumor cell-
specific aberrations has later in part been attributed to immunological consequences9,10, warranting
further investigation of these mechanisms of action and revealing a potential of combining different
treatment options for improved efficacy11. Importantly, by thorough basic research in a variety of
scientific fields and many clinical trials, it is now well established that a complex interplay of
tumor and immune cells12 defines the dynamics of tumor development and that manipulation of
this interplay has the potential to ameliorate disease and even induce long-term cures.
In a landmark paper published in 2013, Chen and Mellman comprehensively reviewed the available
scientific literature and established the concept of the “Cancer-Immunity Cycle”, describing the
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essential steps required for a successful anti-tumor T cell response13: Initial cancer cell death
induces the release of tumor antigens, which are taken up by antigen-presenting cells (APCs)
such as dendritic cells (DCs). APCs then travel to the lymph node, where antigen presentation
results in priming and activation of cytotoxic T cells. Subsequently, activated cytotoxic T cells
traffic via the vasculature to tumors, where they extravasate and infiltrate into the tumor. Cancer
cells expressing the target antigen of primed T cells are then recognized via the T cell receptor
(TCR) complex, inducing T cell activation and tumor cell killing. This simplified model already
illustrates the complexity of processes underlying anti-tumor immunity and thus the vulnerability
to deficiencies at any of the described steps. However, it also provides a theoretical framework for
rational immunotherapeutic intervention with a multitude of potential targets.
1.3 The rise of T cell-based therapies
In the 1980s, the first study showed the anti-tumor potential of adoptively transferred autologous
tumor-infiltrating T lymphocytes in melanoma patients14. Efficacy was improved by increasing
persistence of transferred T cells via nonmyeloablative pre-conditioning15, leading to complete
durable regressions in patients with metastatic melanoma. These results verified earlier obser-
vations from animal experiments16-18, showing that immune cells of a cancer patient had the
potential to eliminate the tumor under certain conditions, but were inhibited in situ (reviewed
in19).
While adoptive cell transfer makes use of activating and expanding T cells to high numbers ex
vivo, investigating an alternative principle of blocking T cell inhibitory signals within the patient
has led to the development of checkpoint inhibition antibodies (reviewed in20-22). These bind
to co-inhibitory receptors on T cells, e.g. programmed cell death protein 1 (PD-1), which is
upregulated upon antigen encounter23, or corresponding ligands such as programmed death-ligand
1 (PD-L1)24, which is often overexpressed on the surface of tumor cells25. This enables sustained
or renewed anti-tumor activity of T cells and has thereby induced durable complete remissions in
entities previously considered mainly incurable such as metastatic melanoma, leading to market
approval by the U.S. Food and Drug Administration (FDA) of seven individual products since
201126 and the denomination as “Breakthrough of the Year” in 2013 by the journal Science 27.
This has made major impact on clinical use of immunotherapy, and immune checkpoint inhibitors
are investigated in numerous clinical trials as mono- or combination therapy for diverse tumor
entities∗.
Both adoptive T cell transfer and checkpoint inhibition approaches require the presence of T
cells with receptor specificity for haplotype-restricted antigenic epitopes presented on class I
major histocompatibility complex molecules (MHC I) of tumor cells. This represents a major
limitation of such approaches relying on original T cell specificity. As spontaneous recognition of
malignantly transformed cells by the immune system is suboptimal in case of tumor development,
in situ therapeutic vaccination approaches are under extensive investigation. However, so far
prediction and validation of appropriate targets is laborious and time-consuming. In addition,
therapeutic vaccination against defined targets in advanced disease is hampered due to local
immunosuppression and antigenic escape28. A number of approaches are being developed to
address these limitations, including targeting of the patient-specific “mutanome”, i.e. more than
∗313 studies found on clinicaltrials.gov as of March 28, 2019
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one predicted epitope29,30. However, even in the case of relevant TCR specificity, anti-tumor
activity can be absent, e.g. due to MHC loss on tumor cells31.
1.4 Manipulating specificity: The concept of T cell re-direction
Regarding these limitations of relying on TCR specificity for cancer treatment, using polyclonal
T cells can provide an advantage by targeting a broad range of potentially tumor-associated
antigens. To overcome inefficient tumor cell recognition, approaches to re-direct polyclonal T cells
to tumor surface antigens via single chain variable fragments (scFvs) have been developed, the
most advanced being bispecific T cell engagers (BiTEs) and chimeric antigen receptors (CARs)
(reviewed in32).
BiTEs are artificial bispecific antibodies composed of two scFvs targeting a tumor surface antigen
and the T cell receptor-associated molecule CD3ε, respectively (Fig. 1, reviewed in33-36). The
scFvs are connected by a flexible, non-immunogenic peptide linker, allowing for cross-linking of T
cells and target tumor cells. This subsequently induces T cell activation and the formation of a
regular immunological synapse, irrespective of MHC expression37, haplotype, TCR specificity, and
co-stimulation38. However, BiTE-mediated activation is not observed in naïve T cells39. Both
CD8+ and CD4+ T cells have been shown to induce apoptosis in tumor cells upon BiTE-mediated
crosslinking by release of cytotoxic granules containing perforin and granzyme B, indistinguishable
from normal T cell receptor-mediated activation40, but maximal lysis is reached faster by CD8+
compared to CD4+ T cells41. Interestingly, patient-derived regulatory T cells (Treg) were able to
trigger BiTE-mediated tumor cell lysis in vitro42. Two- to three-fold expansion of total T cell
numbers in peripheral blood was observed upon BiTE treatment43 and individual BiTE-engaged
T cells are capable of serial killing of multiple tumor cells44, indicating potential even at low
effector-to-target cell (E:T) ratios.
Chimeric antigen receptors also contain an scFv targeting a tumor surface antigen, but are directly
expressed by genetically modified T cells and linked via hinge and transmembrane domains to
intracellular CD3ζ signaling and additional co-stimulatory domains providing T cell activation
upon antigen binding (Fig. 2, reviewed in45-47). As with BiTEs, CAR engagement has been shown
to induce T cell proliferation and serial lysis of tumor cells by both CD4+ and CD8+ T cells, with
CD4+ T cells killing more slowly but persisting longer48. However, atypical synapses are formed
between CAR T cells and target tumor cells, resulting in rapid detachment and faster serial
killing capacity49. in vivo proliferation of over 1,000-fold has been observed for CAR T cells50,51,
while proliferation and persistence strongly depend on the subtype of the CAR-expressing T cell.
In contrast to BiTE therapy relying on activation of resting, antigen-experienced T cells, it has
been shown that for CAR-mediated re-direction, less differentiated cells with higher self-renewal
capacity proliferate more strongly, persist longer, and thus show improved total anti-tumor
activity52,53.
In addition to scFv specificity, the activation potential of a given CAR is influenced by the
length of the hinge region which determines effectivity of cross-linking54,55 and the choice of
co-stimulatory domains. First-generation CARs contained a CD3ζ-derived signaling molecule
only56. Introduction of a CD28 co-stimulatory domain drastically increased CAR T cell activity
of second-generation CARs57,58, which have now advanced to the clinics. A multitude of novel
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Figure 1: The bispecific T cell engager (BiTE) principle. Single chain variable fragments
derived from two monoclonal antibodies directed against a tumor surface antigen (blue) and the
epsilon chain of the T cell receptor-associated molecule CD3 (CD3ε) are connected by a flexible
peptide linker to form a BiTE. By cross-linking a T cell to a target antigen-expressing tumor cell,
the T cell is activated, inducing tumor cell lysis.
compositions, e.g. including additional co-stimulatory domains (third-generation CARs), is
currently under investigation for improved safety, efficacy and persistence of CAR T cells59,60.
1.5 Clinical applications of T cell re-direction therapies
Both BiTE and CAR therapies have been approved for treatment of certain hematological
malignancies. The clinically most advanced agent of the BiTE class is blinatumomab (Blincyto®),
a CD19-targeting BiTE that has first been approved by the FDA for treatment of Philadelphia
chromosome-negative relapsed or refractory precursor B cell acute lymphoblastic leukemia (B-ALL)
in 201461, followed by approval also in Philadelphia chromosome-positive B-ALL in 201762 and
patients in B-ALL remission with minimal residual disease (MRD) in 201863. In a phase 3 study,
blinatumomab therapy was superior to standard-of-care chemotherapy. Complete remissions
were reported in 34% of BiTE-treated patients, but short response durations have been reported
with median overall survival of 7.7 months64. Due to small molecular size, blinatumomab shows
beneficial tissue penetration but limited serum half-life of around 2 h65, requiring continuous
application via infusion pumps in up to five cycles of four weeks66, which is inconvenient for
patients. Furthermore, severe and sometimes fatal toxicities associated with systemic application
have been reported including infections, neurologic events, neutropenia, anemia, and cytokine
release syndrome.
Two products containing CAR-expressing T cells, tisagenlecleucel (Kymriah®) and axicabtagene
ciloleucel (Yescarta®), both also targeting CD19, have recently been FDA-approved for treatment
of B-ALL patients up to 25 years of age in second or later relapse67 and adult large B cell
lymphoma patients without response to or in relapse following at least two previous lines of
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Figure 2: T cell re-direction. A. Target cell lysis by cytotoxic T cells requires T cell receptor
(TCR)-specific recognition of the respective target peptide presented by major histocompatibility
complex I (MHC I) on the target cell surface as well as additional co-stimulatory signals (not
shown). T cell activation and release of cytotoxic granules follows intra-cellular signaling down-
stream of the TCR complex. B. Bispecific T cell engagers (BiTEs) circumvent the requirement of
MHC presentation by directly cross-linking a tumor surface antigen with CD3ε on non-naïve T
cells, inducing the formation of a classical immunological synapse irrespective of TCR specificity
or co-stimulation. C. T cells genetically modified to express a chimeric antigen receptor (CAR)
bind to tumor surface antigens via a single chain antibody displayed on the extracellular part of
the CAR. CAR T cell efficacy in terms of target cell lysis is determined by various parameters,
including the affinity of the single chain to its antigen, the structure of the hinge and transmem-
brane region, and, importantly, the composition of intracellular signaling and co-stimulatory
domains.
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treatment68, respectively. In general, systemic targeting of CD19-expressing cells induces B cell
aplasia. In addition, similar to blinatumomab, severe neurologic toxicities and frequent occurrence
of cytokine release syndrome including fatal cases have been observed, requiring close monitoring
and management of side effects by appropriate countermeasures such as immunosuppressive
regimens69. In addition, relapses are frequently observed, sometimes associated with proliferation
of tumor cell clones that have lost CD19 expression70. While both BiTE and CAR products have
been approved for treatment of hematological malignancies, this is not the case for solid tumors.
Due to the potentially severe systemic side effects, the therapeutic window of these therapies is
narrow. Physical barriers to T cell infiltration into solid tumors, such as high interstitial pressure,
dense stroma, and disorganized vasculature, as well as an immunosuppressive microenvironment
have so far prevented efficacious application. This requires novel approaches and combination
therapies to increase efficacy32.
1.6 Oncolytic viruses: novel immunotherapeutics
In the past decades, oncolytic virotherapy has emerged as a novel form of immunotherapy after
being widely regarded as an impractical, ineffective and even dangerous idea for over a century
(reviewed in71), much like the field of immunotherapy in general. Oncolytic viruses can be found
among different virus families72 and share the characteristic of lytic replication in malignantly
transformed tissue without affecting healthy cells (reviewed in73). First anecdotal observations
of tumor remissions upon infection with influenza were made in the early 20th century74, at a
time when viruses had not even been discovered as infectious agents. Tissue culturing methods
allowing the propagation of viruses advanced the field of virology in the middle of the century75,
simultaneously stimulating studies with oncolytic viruses in animal experiments and humans that
sometimes did not meet scientific standards of modern medical research76. Cancer patients were
treated with infectious body fluids in the hope to induce tumor remissions77, and even tumor cell
lines were intentionally implanted into cancer patients and healthy volunteers to test oncolytic
activity of viruses in vivo78,79.
Fortunately, the field has since advanced to rational scientific evaluation of non-pathogenic viruses
that are of foreign host specificity or attenuated by either passaging on non-human cell lines
or genetic modification. These strategies are exemplified by rodent parvovirus H1 (H1-PV),
oncolytic measles virus vaccine strains, and thymidine kinase-deficient herpes simplex virus
(HSV), respectively. The latter example represents the first application of genetic engineering
for oncolytic viruses, showing enhanced tumor specificity and decreased neurovirulence in the
treatment of glioma in nude mice80 and sparking renewed interest in the field in 1991. Genetic
engineering is now regularly applied in the development of novel oncolytics to increase specificity
and efficacy.
While anti-tumor efficacy of oncolytic virotherapy was initially believed to rely solely on direct
tumor cell lysis with the immune system being an impediment to successful treatment, it is
now appreciated that virus-mediated induction of anti-tumor immune responses represents a
major mechanism of action (reviewed in81-83), in addition to stromal and vascular targeting84.
Immunogenic lysis of infected cells results in the release of tumor antigens, pathogen- and danger-
associated molecular patterns, chemokines, and cytokines and can thus induce local inflammation
and reversion of immunosuppression within the tumor microenvironment, which has been referred
to as “turning an immunologically cold tumor hot”85.
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This naturally encourages combinations of oncolytic viruses with immunotherapeutic approaches.
Indeed, talimogene laherparepvec (T-VEC, Imlygic®), the first and so far only oncolytic thera-
peutic that has been approved by the FDA and the European Medicines Agency (EMA), is a
type I HSV genetically engineered not only for attenuation, but also to achieve increased tumor
immune recognition. The viral genome was modified by disruption of γ-34.5, a gene involved
in suppressing antiviral responses, by translocating US11, a gene preventing host cell protein
synthesis shutoff, for expression under an early rather than a late promoter, by deleting ICP47,
a gene interfering with antigen processing, and by inserting a transgene encoding granulocyte
macrophage colony-stimulating factor to induce APC activation and maturation for enhanced anti-
tumor T cell priming86. T-VEC was approved in 2015 for treatment of advanced melanoma based
on a phase III study showing both local and abscopal efficacy upon intralesional administration87.
No virus was detected in regressing non-injected lesions and abscopal efficacy was attributed to
virus-mediated induction of an anti-tumor T cell response88. This demonstrates the potential of
oncolytic virotherapy to evoke systemic, polyclonal T cell responses directed against solid tumors
and thus warrants investigations of combining oncolytic virotherapy and T cell-based therapies.
It has been shown in earlier animal experiments that local treatment with oncolytic Newcastle
disease virus, an avian paramyxovirus, can induce systemic sensitivity to immune checkpoint
inhibition89. A similar effect has later also been observed in triple-negative breast cancer patients
after injection of an oncolytic Maraba virus90. Consequently, clinical evaluation of T-VEC in
combination with immune checkpoint inhibitors has been initiated91,92.
1.7 Measles vaccine viruses as oncolytic agents
A promising platform for oncolytic virotherapy has been developed based on live attenuated
measles virus vaccine strains (MV, reviewed in93-96). The measles virus is a member of the genus
Morbillivirus in the family Paramyxoviridae with a non-segmented, single-stranded, negative sense
RNA genome containing 15,894 nucleotides (nt) and six genes encoding six structural and two
additional regulatory proteins97-99 (Fig. 3). Untranscribed RNA of 107 and 109 nt in the 3’ leader
and 5’ trailer sequences, respectively, contain regulatory elements for encapsulation, transcription,
and replication100,101. Nucleocapsid (N) proteins, each binding six nucleotides of the genome and
thus requiring the genome to be divisible by six for assembly of functional particles102,103, form a
helical structure104 that together with the large (L) protein and the phosphoprotein (P) is referred
to as ribonucleoprotein complex (RNP). The L protein is the RNA-dependent RNA polymerase
of the measles virus and requires P protein-mediated interaction with measles RNA for both
transcription and replication of the genome105-107. Binding of a fully assembled RNP complex by
matrix (M) proteins attaching to the inner layer of the host cell membrane inhibits transcription
and induces budding of virus particles108. Hemagglutinin (H) and fusion (F) transmembrane
glycoproteins are inserted into the host cell membrane as tetramers and trimers, respectively. H
proteins, which are present both on the surface of infected cells and on free virus particles, attach
to cell entry receptors, inducing fusion with the target cell via conformational changes in the
F protein109. By this, measles virus-infected cells can form large multinucleated syncytia with
uninfected neighboring cells110. Furthermore, measles virus can exploit cell-to-cell contacts for
spreading111. C and V accessory proteins are alternatively expressed from the P open reading
frame (ORF) by usage of an alternative reading frame and by mRNA editing, respectively, and
are involved in measles virulence by interfering with the host cell-intrinsic antiviral interferon
response112,113. Stop signals at the 5’ end of the ORFs are followed by three-nucleotide intergenic
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Figure 3: Measles virus genome (A) and structure (B). A. The negative sense RNA
genome of the measles virus contains six genes arranged as indicated, encoding six structural
proteins. Two additional regulatory proteins, C and V (not shown), are encoded in the P region.
The viral genome also contains non-coding RNA between transcription units as well as in the 3’
leader (3’ ld) and 5’ trailer (5’ tr) sequences, which includes regulatory elements. B. The genome
is encapsulated by the N protein, which binds to proteins P and L, forming the ribonucleoprotein
complex (RNP) required for genome replication and transcription into positive sense mRNA.
The M protein connects the RNP to the viral transmembrane glycoproteins H and F, facilitating
budding of viral progeny from the host cell. H and F are present in the lipid bilayer as tetramers
and trimers, respectively, and mediate host cell entry via binding to cellular receptors and
induction of membrane fusion.
regions, at which the viral polymerase can fall off the genome with a particular probability, leading
to an expression gradient of the encoded genes in the direction of gene expression, i.e. from 3’ to
5’114.
In the 1970s, cases of tumor regression upon contraction of measles virus infection were reported115,
indicating oncolytic potential. However, human-pathogenic wild-type measles virus is the causative
agent of measles, a disease which is clinically characterized by flu-like symptoms, fever, skin rash,
Koplik’s spots and respiratory tract symptoms116 due to infection of epithelial cells using nectin-4
as entry receptor111,117,118. Signaling lymphocytic activation molecule (SLAM, CD150) represents
an additional entry receptor for wild-type measles virus, enabling infection of dendritic cells, T and
B cells, and monocytes119. This can result in immunosuppression and subsequent complications
by secondary infections such as pneumonia120. In rare cases of persistent infection, the central
nervous system can be affected, leading to fatal subacute sclerosing panencephalitis121,122. Live
attenuated vaccines for immunization against this potentially fatal virus have been in use since
the 1960s123-125 and have an excellent safety record, with no observed reversion to infectious
wild-type virus126. For attenuation, wild-type viruses were serially passaged on non-human
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cells97. Due to this, the viruses acquired mutations including a single point mutation in the
H gene causing adaptation to the usage of CD46 as preferred cell entry receptor127-130. CD46
is a complement-regulatory protein present on all nucleated human cells131 that is frequently
upregulated on tumor cells as an immune escape mechanism, which provides a natural oncotropism
to measles vaccine viruses93. In addition, mutations in the virulence factors C and V decrease the
ability of attenuated measles vaccine viruses to interfere with the antiviral defense mechanisms
of the host cell132,133, requiring defective interferon signaling as often observed in malignantly
transformed cells for propagation.
Tumor specificity can be further enhanced by genetic engineering using an established reverse
genetics system134-137. Natural virus tropism can be abrogated by mutations in the H gene and
MV can be re-targeted to cell surface structures by transgenic expression of e.g. receptor ligands
or scFvs on the C-terminal extracellular domain of the H protein (reviewed in93). In addition,
introduction of microRNA target sites into the genome has been shown to limit viral replication
to tissues not expressing the corresponding microRNA138-140.
Moreover, therapeutic or diagnostic transgenes can be introduced into the genome, which has
led to the development of a number of pre-clinically and clinically tested oncolytic measles virus
constructs. Most advanced are vectors of the Edmonston lineage encoding sodium iodide symporter
for radiotherapeutic and imaging purposes (MV-NIS) and carcinoembryonic antigen for in vivo
viral gene expression analyses (MV-CEA), respectively. For these viruses, clinical studies have
confirmed safe delivery by diverse routes of administration and cases of anti-tumor efficacy have
been observed (reviewed in141). A notable case of complete remission of multiple myeloma upon
injection of a single dose of MV-NIS has been described142. Further pre-clinical development has
yielded promising results for MV constructs armed with immunomodulatory transgenes targeting
diverse tumor immune escape mechanisms, including GM-CSF to promote APC activation
and maturation and thus T cell priming143, Helicobacter pylori neutrophil-activating protein
to promote inflammation and anti-tumor T cell responses144, or tumor-associated antigens for
therapeutic vaccination145. Recent work in our lab showed delayed tumor growth and prolonged
survival in immunocompetent C57BL/6 mice bearing subcutaneous B16 murine melanoma tumors
treated with MV encoding checkpoint inhibitors146 and complete tumor remissions in 90% of
animals treated with an IL-12-encoding MV in an MC38 murine colon carcinoma model. Efficacy
was dependent on CD8+ T cells, as evidenced by depletion experiments147.
Oncolytic measles viruses are attenuated and have a natural oncotropism. Routine vaccination
and clinical trials in cancer patients have demonstrated safety. Moreover, MV replication is strictly
cytosolic without any risk of insertional mutagenesis. MVs are strongly immunogenic and MV-
induced syncytia formation facilitates spread as a bystander effect and induces immunogenic cell
death. Furthermore, there is strong pre-clinical evidence for efficacy in combination with additional
immunotherapeutics. The established reverse genetics system and large transgene capacity add
to the beneficial properties of MV as an oncolytic agent. Oncolytic measles virotherapy thus
provides a safe, versatile and efficacious platform for combination immunotherapies.
1.8 Aim of the study
T cell re-direction by both bispecific T cell engagers (BiTEs) and chimeric antigen receptors
(CARs) has shown promising results in the treatment of hematological malignancies. However,
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Figure 4: Proposed mechanism of action of combined oncolytic measles virus and T
cell re-direction immunotherapy. Suppression of anti-tumor T cell responses and toxicities
associated with systemic application of BiTEs and CAR T cells so far prevented approval of such
therapies in solid tumors. We propose the following mechanism of action for successful oncolytic
measles virus (MV) and T cell re-direction combination therapy. A. Malignant transformation and
suppressed anti-viral immunity promote the infection of tumor cells by MV. B. In the course of
viral replication and spread throughout the tumor, infected cells fuse with neighboring tumor cells,
forming large syncytia (grey). Virus-induced immunogenic cell death results in local inflammation
and the recruitment of immune cells, creating a favorable environment for anti-tumor (CAR) T
cell activity. In addition, MV-encoded BiTEs are expressed locally by infected cells, recruiting T
cells to lyse tumor cells without systemic toxicities.
limited efficacy due to physical exclusion and immunosuppression of T cells and severe toxicities
associated with systemic treatment prevent successful application in solid tumors.
Oncolytic virotherapy provides ideal properties for combination treatment: Tumor-specific cell
lysis causes debulking and can facilitate T cell infiltration. Furthermore, virus-mediated immuno-
genic tumor cell death and local inflammation have the potential to reverse immunosuppression
and provide antigen-agnostic in situ vaccination148. In addition, locally restricted expression
of systemically toxic transgenes can enhance anti-tumor efficacy while preventing side effects.
Oncolytic measles vaccine strain viruses (MV) can be safely administered and cause tumor remis-
sions in cancer patients. T cell-mediated efficacy and potential for combination immunotherapy
has been demonstrated in pre-clinical studies.
We therefore hypothesized that oncolytic measles virotherapy can support T cell re-direction
therapies of solid tumors by tumor debulking and reversion of immunosuppression (Fig. 4).
Furthermore, we hypothesized that tumor-targeted BiTE expression by genetically modified MV
can achieve local recruitment of resting T cells and enhance anti-tumor immune responses.
To test these hypotheses, we first generated BiTE-encoding MV to analyze efficacy in vitro and
in vivo in the context of an intact immune system. Specific aims of this project included:
• Generation of a syngeneic murine tumor model susceptible to MV entry and BiTE binding
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via expression of human antigens
• in vitro evaluation of MV-BiTE vectors regarding replicative and cytotoxic potential
• Assessing functionality of MV-encoded BiTEs in vitro in terms of target cell binding and
mediating specific tumor cell lysis by T cells
• Efficacy analysis of MV-BiTE using in the context of an intact immune system in vivo
• Dissecting the mechanism of action of MV-BiTE by immunological analyses ex vivo
Re-direction by CARs rather than BiTEs allows the use of a more defined antigen-specific effector
cell population in terms of cell number and activation state. Establishing a CAR model to be
used for analyses of MV-mediated effects on infiltration, anti-tumor activity, and persistence
of T cells was the aim of the second part of this study. For longitudinal monitoring of T cell
distribution in vivo via non-invasive magnetic resonance imaging, a protocol for labeling of T
cells with iron oxide nanoparticles was to be evaluated.
The complexity of the immune system in the context of malignant disease in combination with
oncolytic viruses requires careful choice of potential treatment regimens. Mathematical modeling
can provide support in this respect by identification of crucial determinants of treatment success
and by predicting outcomes of experimental treatment schedules in silico. To achieve this, we
collaborated with mathematicians to conceive a model describing the dynamic interplay between
tumor and immune compartments in the context of oncolytic virotherapy in combination with T
cell re-direction strategies.
My overarching aim and personal motivation for my doctoral studies was to advance the de-
velopment of safe and effective immunotherapies for cancer treatment, based on the promising
combination of oncolytic viruses and T cell re-direction.
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2 Materials and Methods
2.1 Materials
2.1.1 Cell lines
Cell line Description Obtained from
293GP HEK 293T cells stably expressing gag and pol
proteins, used for production of retroviral vectors
by transient transfection
D. Abate-Daga, Tampa, FL, USA
B16 murine melanoma cell line D. Nettelbeck, Heidelberg
B16-CD20 B16 cells stably expressing human CD20 C. Großardt, Heidelberg
B16-CD20-CD46 B16-CD20 lentivirally transduced for stable
expression of human CD46
B16-CD46 B16 cells lentivirally transduced for stable
expression of human CD46
Granta-519 human mantle cell lymphoma cell line expressing
human CD20
DSMZ
HEK 293T human embryonal kidney cells transformed with
simian virus 40 large T antigen, used for
production of lentiviral vectors by transient
transfection
ATCC
HPAC human pancreatic adenocarcinoma cell line D. Abate-Daga, Tampa, FL, USA
PC05 primary pancreatic tumor cell culture N. Kang and C. R. Ball, Heidelberg
Vero African green monkey kidney epithelial cell line
for production of recombinant measles viruses
ATCC
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2.1.2 Cell culture media
Component Obtained from
Advanced DMEM/F-12 medium Thermo Fisher Scientific
Dulbecco’s Modified Eagle’s Medium (DMEM), high glucose, GlutaMAX
Supplement, pyruvate
Thermo Fisher Scientific
Fetal bovine serum (FBS) Biosera and PAN-Biotech
Human serum from human male AB plasma, USA origin, sterile filtered Sigma-Aldrich
Opti-MEM I Reduced Serum Medium, GlutaMAX Supplement Thermo Fisher Scientific
OptiPRO SFM Thermo Fisher Scientific
Roswell Park Memorial Institute 1640 medium (RPMI), GlutaMAX Supplement Thermo Fisher Scientific
X-VIVO 15, serum-free, L-glutamine, without gentamicin or phenol red Biozym/ Lonza
2.1.3 Oligonucleotides
Name Sequence 5’ to 3’
mCD3 Fw GTGCAACCAGGCAAATCTCT
His-tag BiTE Rev GTGGTGATGATGGTGGTGAG
T-bet Fw TAAGCAAGGACGGCGAATGTT
T-bet Rev TGCCTTCTGCCTTTCCACAC
L13A Fw GGCTGCCGAAGATGGCGGAG
L13A Rev GCCTTCACAGCGTACGACCACC
FoxP3 Fw GGCCCTTCTCCAGGACAGA
FoxP3 Rev GCTGATCATGGCTGGGTTGT
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2.1.4 Buffers and chemicals
Component Manufacturer
1-Step Ultra TMB-ELISA Substrate Solution Thermo Fisher Scientific
4’,6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich
Accutase solution Sigma-Aldrich
ACK Lysing Buffer Lonza
Antibiotic Antimycotic Solution (ABAM) (100x) Sigma-Aldrich
Aqua ad Injectabilia (RNase-free H2O) B. Braun
B27 supplement Thermo Fisher Scientific
Bovine serum albumin (BSA) Sigma-Aldrich
D-Glucose (Dextrose) Thermo Fisher Scientific
Dimethyl sulfoxide (DMSO), sterile filtered Sigma-Aldrich
Dulbecco’s Phosphate Buffered Saline (DPBS), no calcium, no magnesium Thermo Fisher Scientific
ELISA Stop Solution Takara Bio
Fibroblast growth factor 10 (FGF10) R&D Systems
Fibroblast growth factor basic (FGF2) R&D Systems
Ficoll® Paque PLUS GE Healthcare
FuGENE® HD Transfection Reagent Promega
Heparin sodium salt Sigma-Aldrich
HEPES solution (1M) Sigma-Aldrich
Imidazole Carl Roth
Isopropyl alcohol (2-propanol 99,8%) Carl Roth
Kanamycin solution 10 mg/mL in 0.9% NaCl, suitable for cell culture Sigma-Aldrich
L-Glutamine (200 mM) Thermo Fisher Scientific
Lipofectamine 2000 Thermo Fisher Scientific
MS4A1 Human Recombinant Protein (CD20 full length) Abnova
Nodal R&D Systems
Penicilin-Streptomycin (Pen/Strep) (5,000 U/mL) Thermo Fisher Scientific
Polybrene (Hexadimethrene bromide) Sigma-Aldrich
Polyethyleneimine, branched, average Mw 25.000 by LS Sigma-Aldrich
Protamine sulfate Sigma-Aldrich
Recombinant human IL-2 BioLegend
RetroNectin Recombinant Human Fibronectin Fragment Clontech/Takara Bio
Sodium Chloride Carl Roth
Trypan Blue solution, 0.4%, sterile filtered, suitable for cell culture Sigma-Aldrich
Trypsin-EDTA (0.05%), phenol red Thermo Fisher Scientific
Tween20 Biotium
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2.1.5 Antibodies
Name Description Manufacturer
anti-HA-biotin rat IgG1κ, clone 3F10, 1:500 for
ELISA
Sigma-Aldrich
anti-HA-PE mouse IgG1κ, clone GG8-1F3.3.1, 1:5
for flow cytometry
Miltenyi Biotec
anti-His-FITC mouse IgG1κ, clone 13/45/31-2, 1:5
for flow cytometry
Dianova
anti-human CD20-PE mouse IgG2bκ, clone 2H7, 1:5 for flow
cytometry
BD Biosciences
anti-human CD3 clone OKT3, 0.5 µg/mL for
stimulation of human T cells
Abcam
anti-human CD46-PE mouse IgG1κ, clone TRA-2-10, 1:20
for flow cytometry
BioLegend
anti-mCD25-PE-Cy7 rat IgG1κ, clone PC61, 1:100 for flow
cytometry
BD
anti-mCD3-PerCP-Cy5.5 rat IgG2bκ, clone 17A2, 1:100 for flow
cytometry
BD
anti-mCD4-APC-Cy7 rat IgG2bκ, clone GK1.5, 1:100 for
flow cytometry
BD
anti-mCD69-PE Armenian hamster IgG, clone H1.2F3,
1:80 for flow cytometry
BioLegend
anti-mCD8a-APC rat IgG2aκ, clone 53-6.7, 1:100 for
flow cytometry
BD
anti-mCTLA4-FITC Armenian hamster IgG, clone 1B8 Thermo Fisher Scientific
Armenian hamster IgG-PE isotype control, clone HTK888 BioLegend
Kiovig human IgG and IgA, 1:60 for blocking
in flow cytometry
Baxalta
mouse IgG1κ-FITC isotype control, clone X40 BD
mouse IgG1κ-PE isotype control, clone MOPC-21 BD
Protein L Biotin 1:300 for flow cytometry Genscript
Purified Rat Anti-Mouse CD16/CD32
(Mouse BD Fc Block)
rat IgG2bκ, clone 2.4G2, 1:100 for
blocking in flow cytometry
BD
rat IgG2aκ-APC isotype control, clone R35-95 BD
rat IgG2bκ-APC-Cy7 isotype control, clone A95-1 BD
rat IgG2bκ-PerCP-Cy5.5 isotype control, clone A95-1 BD
Streptavidin-HRP 1:500 for ELISA Dianova
Streptavidin-PE 1:100 for flow cytometry BioLegend
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2.1.6 Plasmids
Name Description
pcDI-dsRed mammalian expression vector encoding Discosoma sp. red
fluorescent protein
pCG-L mammalian expression vector encoding the measles virus large
protein
pCG-N mammalian expression vector encoding the measles virus
nucleocapsid protein
pCG-P mammalian expression vector encoding the measles virus
phosphoprotein
pcpNSe-H-ATU vector encoding Edmonston B vaccine lineage measles virus
cDNA antigenome containing an additional transcription unit
downstream of the H open reading frame (ORF) for virus
rescue via RNA polymerase II
pcpNSe-H-hCD3xCD20 vector encoding Edmonston B vaccine lineage measles virus
cDNA antigenome with hCDxCD20 BiTE downstream of the H
ORF for virus rescue via RNA polymerase II
pcpNSe-H-hCD3xCEA vector encoding Edmonston B vaccine lineage measles virus
cDNA antigenome with hCDxCEA BiTE downstream of the H
ORF for virus rescue via RNA polymerase II
pcpNSe-H-mCD3xCD20 vector encoding Edmonston B vaccine lineage measles virus
cDNA antigenome with mCDxCD20 BiTE downstream of the
H ORF for virus rescue via RNA polymerase II
pcpNSe-H-mCD3xCEA vector encoding Edmonston B vaccine lineage measles virus
cDNA antigenome with mCDxCEA BiTE downstream of the H
ORF for virus rescue via RNA polymerase II
pcpNSe-ld-eGFP-mCD3xCD20 vector encoding Edmonston B vaccine lineage measles virus
cDNA antigenome with enhanced green fluorescent protein in
the leader position and mCDxCD20 BiTE downstream of the H
ORF for virus rescue via RNA polymerase II
pLTR-RD114A mammalian expression vector encoding RD114 envelope
glycoprotein; RRID: Addgene 17576
pMDLg/pRRE, pRSV-rev, pMD2.VSV-G vectors for production of non-replication competent lentiviruses
pMSGV1-Ha1-4.117scFv-28-BBZ retroviral vector encoding a third-generation chimeric antigen
receptor targeting human prostate stem cell antigen (PSCA3)
pMSGV1-Ha1-4.117scFv-28Z retroviral vector encoding a second-generation chimeric antigen
receptor targeting human prostate stem cell antigen (PSCA2)
pRRL.pptCMV-hCD46BC1.PRE transfer vector encoding human CD46 for lentivirus production
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2.1.7 Recombinant measles viruses
Virus name Description
MV unmodified measles virus of the Edmonston B vaccine lineage
MV-H-hCD3xCD20 measles virus of the Edmonston B vaccine lineage encoding an hCD3xCD20
BiTE downstream of the H ORF
MV-H-hCD3xCEA measles virus of the Edmonston B vaccine lineage encoding an hCD3xCEA
BiTE downstream of the H ORF
MV-H-mCD3xCD20 measles virus of the Edmonston B vaccine lineage encoding an
mCD3xCD20 BiTE downstream of the H ORF
MV-H-mCD3xCEA measles virus of the Edmonston B vaccine lineage encoding an mCD3xCEA
BiTE downstream of the H ORF
MV-IgG measles virus of the Edmonston B lineage encoding human immunoglobulin
G4 downstream of the H ORF
MV-ld-eGFP-H-mCD3xCD20 measles virus of the Edmonston B vaccine lineage harboring an
eGFP-encoding transgene in the leader position and an mCD3xCD20
BiTE-encoding sequence downstream of the H ORF
MV-Nivo measles virus of the Edmonston B vaccine lineage encoding Nivolumab
downstream of the H ORF
MV-Pembro measles virus of the Edmonston B vaccine lineage encoding Pembrolizumab
downstream of the H ORF
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2.1.8 Kits and consumables
Product Manufacturer
Amicon Ultra-15, PLGC Ultracel-PL Membran, 10 kDa Merck
BCA Protein Assay Kit, Calbiochem-Novabiochem Novagen
Cell lifter Corning
Cell strainer 100 µm Falcon
Colorimetric Cell Viability kit III PromoCell
CytoTox 96 Non-Radioactive Cytotoxicity Assay kit Promega
Maxima H Minus First Strand cDNA Synthesis Kit and oligo(dT)18 primers Thermo Fisher Scientific
Needles (26G) B. Braun
Nunc MaxiSorp plates Thermo Fisher Scientific
Pan T cell Isolation Kit II, mouse Miltenyi Biotec
Pestle for microcentrifuge tube schuett-biotec
Power SYBR Green PCR Master Mix Thermo Fisher Scientific
QIAshredder homogenizer columns Qiagen
RNAlater RNA Stabilizing Reagent Qiagen
RNeasy Protect Mini Kit Qiagen
Syringes (1 mL) B. Braun
2.2 Methods
2.2.1 MV-BiTE analysis in vitro
Generation of oncolytic measles virus (MV) genomes of the Edmonston B vaccine lineage encoding
bispecific T cell engagers (BiTEs) and of lentiviral vectors encoding human CD46 for stable
expression in transduced target cells was performed prior to the start of my doctoral studies and
will be described here in brief. Detailed descriptions of the applied molecular cloning methods
can be found elsewhere149-151. General methods describing the cloning, rescue, and propagation
of recombinant oncolytic measles viruses and in vitro testing of virus constructs as well as of
encoded immunomodulators have been published as a video protocol accompanied by a written
manuscript134.
General cell culture
Cell culture was performed in class II biological safety cabinets. Cells were propagated in
humidified incubators at 37°C and 5% CO2. Adherent cells were grown in tissue-culture treated
T75 or T175 cell culture flasks with filter caps. Murine melanoma B16 cells and derivatives and
human pancreatic adenocarcinoma (HPAC) cells were cultured in Roswell Park Memorial Institute
medium 1640 (RPMI) supplemented with 10% fetal bovine serum (FBS). HEK 293T cells, Vero
cells, and 239GP cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
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with 10% FBS. PC05 cells were cultured in DMEM Advanced F12+ medium supplemented with
1% glutamine, 2% B27 supplement, 5 mM HEPES, 12 µg/mL heparin, 6 mg/mL glucose, 10
ng/mL FGF2, 20 ng/mL FGF10, and 20 ng/mL Nodal, and accutase was used to detach cells. In
general, cells were detached every two to three days by addition of 0.05% Trypsin-EDTA solution
after washing wells with Dulbecco’s Phosphate Buffered Saline (DPBS) and sub-cultured 1:2 –
1:20, according to cell density, in fresh medium. Cells were frozen for long-term storage after
expansion at 1x106 cells/ mL in 1 mL cell type-specific medium supplemented with 20% FBS and
10% DMSO in screw-cap tubes. After resuspending in freezing medium, cells were directly placed
in a Freezing Container (Thermo Fisher Scientific) containing isopropyl alcohol and transferred
to -80°C. The next day, vials were transferred to liquid nitrogen in a designated storage tank.
Frozen cells were thawed at 37°C for 1 min, immediately transferred to a 15 mL tube containing
9 mL cell type-specific medium, pelleted at 300 x g for 5 min, resuspended in 10 mL medium,
and transferred to a T75 cell culture flask for propagation.
Generation of murine melanoma cell lines stably expressing human CD46
For stable expression of human CD46 in murine cell lines to allow for measles vaccine virus entry,
I had generated replication-deficient lentiviruses encoding human CD46 isoform BC1 (hCD46BC1)
during my master’s thesis project prior to the start of my PhD studies as described previously149.
Briefly, 1x107 HEK 293T cells had been incubated overnight on 15 cm dishes in 10 mL DMEM,
10% FBS before transient transfection. Transfection mix was prepared by adding 2.5 mL DMEM
containing 126 µL 18 mM polyethylenimine (PEI) to 2.5 mL DMEM containing DNA plasmids
(12.5 µg pMDLg/pRRE, 6.25 µg pRSV-rev, 9 µg pMD2.VSV-G, and 28 µg of transfer vector
pRRL.pptCMV-hCD46BC1.PRE, into which I had introduced the hCD46BC1-encoding sequence
from complementary DNA (cDNA)), mixing, and incubating at room temperature for 30 min.
Medium on cells was replaced by fresh 10 mL DMEM, 10% FBS, transfection mix was added, and
cells were incubated at 37°C, 5% CO2 overnight. The next day, medium was replaced with 12 mL
fresh DMEM, 10% FBS, and incubation was continued for 24 h. Supernatant containing lentivirus
particles was harvested and 12 mL fresh medium were added to the dish. The supernatant was
kept at 4°C and stored until pooling with a second harvest after incubation of cells for another 24
h. For purification of lentiviruses, pooled supernatants were centrifuged for 5 min at 1,000 x g
and 4°C prior to passing through 0.22 µm filters. Filtrates were then centrifuged for 2 h at 70,000
x g and pelleted lentiviruses were resuspended in 50 µL DPBS.
Murine melanoma cells B16 and B16-CD20, respectively, at 70% confluence were inoculated
with purified lentivirus suspension diluted 1:100 in a total volume of 800 µL RPMI, 10% FBS,
containing 8 µg/mL Polybrene. After incubation at 37°C, 5% CO2 overnight, cells were washed
with PBS and detached from the plate by incubation with 250 µL Trypsin-EDTA solution for 5
min at room temperature. Cells were pelleted by centrifugation for 5 min at 300 x g, resuspended
in 2 mL RPMI with 10% FBS and transferred to a T25 cell culture flask for expansion at 37°C,
5% CO2. After 13 days, CD46 expression was analyzed by flow cytometry using anti-CD46-PE
antibody and CD46-positive cells were sorted into individual wells of a 96-well round-bottom plate
by fluorescence-associated cell sorting using a BD FACSAria II flow cytometer. After outgrowth
of clonal colonies, these were analyzed for CD46-expression on an LSR II flow cytometer and
subjected to MV susceptibility testing. For this, 3x105 cells were inoculated with 3x105 and 3x104
cell infectious units (ciu), respectively, of MV encoding enhanced green fluorescent protein in the
leader position and mCD3xCD20 BiTE downstream of the H gene (MV-ldeGFP-H-mCD3xCD20)
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in 1 mL Opti-MEM. After 48 h of incubation at 37°C, 5% CO2, cells were analyzed for syncytia
formation and eGFP expression using ZEISS AxioVert 200 fluorescence microscope and AxioVision
software.
BiTE Design
Sequences of single chain variable fragments (scFvs) targeting human CD3 (antibody clone OKT3)
and murine CD3 (antibody clone 145-2C11) were obtained from publicly available databases
(EMBL-EBI European Nucleotide Archive: A22261, A22259; IMGT: AF000356, AF000357).
Sequences were codon-optimized for expression in mice and synthesized by GeneArt Strings and
Eurofins Genomics, respectively. scFvs against human CD20 and carcinoembryonic antigen (CEA)
based on antibody clones B9E9 and MFE-23, respectively, were derived from anti-genomes of
measles virus constructs re-targeted to these antigens by scFV fusion to hemagglutinin143,152
by polymerase chain reaction (PCR). Variable heavy (VH) and light (VL) chains are connected
by peptide linkers containing thrice the amino acid sequence of four glycin (G) and one serine
(S) residues (G4S)3 to enable conformation analogous to the complementary-determining region
(CDR) of the original antibodies153,154. A shorter version of the linker (G4S) was introduced
between the two scFvs encoded in tandem by one BiTE sequence.
Generation of oncolytic measles viruses from anti-genomic DNA
Measles virus particles were rescued by co-transfection of Vero cells with recombinant DNA
encoding the viral anti-genome (pcp-NSe) and plasmids encoding the N, P, and L proteins using
the established reverse genetics system135-137. One day before transfection, 2x105 Vero cells were
seeded in a volume of 2 mL DMEM, 10% FBS, per well on a six well plate and incubated at 37°C
and 5% CO2 overnight to achieve approximately 70 % confluence. The next day, in a total volume
of 200 µL DMEM, 5 µg of the respective anti-genomic DNA, 500 ng each of pCG-N and pCG-L,
and 100 ng each of pCG-P and pcDI-dsRed as a reporter of transfection efficiency were mixed.
18.6 µL of FugeneHD were added and the tube was mixed immediately by flicking, followed by
25 min incubation at room temperature (RT). Medium on Vero cells was replaced by 1.8 mL
DMEM, 2% FBS, 50 µg/mL kanamycin. The transfection mix was added dropwise to the well
and distributed by swirling. Cells were incubated at 37°C, 5% CO2 overnight before medium was
replaced with 2 mL DMEM, 2% FBS, 50 µg/mL kanamycin. Incubation was continued and cells
were observed daily by microscopy to detect syncytia formation. When syncytia were visible,
cells were scraped into 1 mL Opti-MEM using a cell lifter to harvest viruses, followed by brief
vortexing of the suspension prior to further virus propagation.
Propagation of oncolytic measles viruses
6x106 Vero cells were seeded in 12 mL DMEM, 10% FBS, on 10 cm dishes and incubated overnight
to reach 80-90% confluency. Medium was replaced with 3 mL Opti-MEM and suspension obtained
from MV rescue was added. Cells were incubated for at least 3 h at 37°C before 6 mL DMEM,
10% FBS were added and cells were transferred to 32°C, 5% CO2 for further incubation. After 48
to 72 h, when syncytia had spread throughout the whole cell monolayer, cells were scraped into 1
mL Opti-MEM. The suspension was snap-frozen in liquid nitrogen, thawed at 37°C, vortexed
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three times for 10 s at half-maximal speed, and centrifuged at 5,000 x g for 5 min to remove cell
debris. 100 µL of the resulting cell-free supernatant were used for titer determination and the
rest was stored at -80°C.
For further propagation of viruses, 4x106 Vero cells per dish were seeded in 12 mL DMEM,
10% FBS, on 15 cm dishes and incubated overnight. Vero cells were inoculated with virus at a
multiplicity of infection (MOI) of 0.03, i.e. 0.03 cell infectious units (ciu) per Vero cell (or 3x104
ciu per 106 cells), in a final volume of 8 mL Opti-MEM per plate. After at least 2 h of incubation
at 32°C, 5% CO2, 8 mL DMEM with 10% FBS were added to each plate and incubation was
continued until syncytia had spread across the entire cell layer approximately 60 h post inoculation.
To harvest virus, media was removed and cells were scraped from the plate bottom. Scraped cells
infected with the same virus constructs were pooled in 50 mL tubes, subjected to a freeze-thaw
cycle, vortexed briefly, and centrifuged at 2,500 x g for 5 min. Supernatants were transferred to
screw-cap tubes in 500 µL aliquots and stored at -80°C.
Viral titer determination by Vero titration assay
For evaluation of viral titers, 90 µL DMEM, 10% FBS were transferred to each well of a 96-well
plate. Into each well of the first row, 10 µL of one virus aliquot were added after brief vortexing to
homogenize the suspension, yielding eight technical replicates. Using a multi-channel pipet, wells
were mixed by pipetting up and down for at least 10 times and 10 µL of each well were transferred
to the next row. This was repeated for the whole plate to prepare serial ten-fold dilutions of the
virus suspension. 10 µL from each well of the last row were discarded to obtain equal volumes.
1.5x104 Vero cells in 100 µL DMEM, 10% FBS, were added to each well and plates were incubated
for 48 h at 37°C, 5% CO2. By light microscopy, the row with highest dilution of virus showing
formation of syncytia was identified. Syncytia were counted in each well of that row, and the
average number of syncytia per well was assessed. Viral titers were calculated by multiplication
of the identified average number of syncytia with the dilution factor of the respective row (102 for
the first row, containing 10-2 mL virus per well), yielding values of cell infectious units per mL
virus suspension. For each virus, average titers of three independent aliquots were determined
and used to calculate amounts of viral suspension used for further experimentation.
Viral replication kinetics
For assessing viral replication kinetics by one-step growth curve experiments, 1x105 Vero, Granta-
519, or murine melanoma cells per well were seeded in 1 mL of cell type-specific medium on
12-well plates in duplicates for each of the six time points of interest (12, 24, 36, 48, 72, 96 h post
inoculation) and incubated at 37°C, 5% CO2. After 24 h, medium on cells was replaced with 300
µL Opti-MEM containing the respective virus at an MOI of 1 and cells were incubated for 12 h
before medium was replaced by 1 mL of cell type-specific medium per well. At indicated time
points, cells were scraped directly into the medium, snap-frozen in liquid nitrogen and stored
at -80°C until samples from all time points were collected. Samples were thawed, vortexed, and
centrifuged at 2,500 x g for 5 min simultaneously and titers were determined for each sample in
quadruplicates on Vero cells by titration assay.
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Virus-mediated cyototoxicity
To assess cytotoxic potential of oncolytic measles viruses, cell viability following virus inocula-
tion was determined by 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
(XTT) assay. For this, 1x105 Vero or murine melanoma cells per well were seeded in 1 mL of cell
type-specific medium on 12-well plates in triplicates for each time point and incubated at 37°C,
5% CO2 for 24 h. Medium was then replaced with 300 µL Opti-MEM only (mock) or Opti-MEM
containing the respective virus at an MOI of 1. Cells were incubated for 12 h before medium
was replaced by 1 mL of cell type-specific medium per well. At 12, 24, 36, 48, 72, and 96 h
post inoculation, metabolic activity of cells was assessed using Colorimetric Cell Viability kit III
according to the manufacturer’s instructions. Briefly, medium was removed and 300 µL of freshly
prepared substrate solution were added to each well and incubated until the reagent in the mock
control wells had turned deep red. Supernatant was collected from each well and stored at -20°C
until samples from all time points had been obtained. After thawing, 100 µL of each sample
were transferred to a 96-well plate and absorbance at 450 nm was measured using Infinite M200
microplate reader and i-control software v1.6.19.2 (Tecan). Background absorbance at a reference
wavelength of 630 nm was subtracted for each sample. Mean percentages were calculated for each
sample relative to average mock values obtained for the respective time point.
Production, isolation and purification of MV-encoded BiTEs
For production of BiTEs from virus-infected cells (virus-derived BiTEs, vBiTEs), Vero cells were
grown to 70% confluency in T175 flasks in 12 mL DMEM, 10% FBS at 37°C, 5% CO2. Medium
was removed and cells were washed twice with PBS to remove residual FBS. 12 mL serum-free
medium OptiPRO SFM containing BiTE-encoding MV at MOI of 0.03 was added to the cells.
After 12 h of incubation, medium was replaced with 12 mL fresh OptiPRO SFM. Approximately
40 h post virus inoculation, when syncytia had formed but not yet spread entirely across the
flask, cells were transferred to 32°C, 5% CO2 for additional 24 h of incubation to enhance BiTE
secretion while preventing bursting of infected cells. Supernatants were then carefully collected
and transferred to 50 mL tubes. Cell debris was removed by centrifugation for 5 min at 2,500 x g
and cell-free supernatant was sterile-filtered by passing through a 0.22 µm filter with a syringe.
Affinity exchange chromatography was performed with QIAquick Ni-NTA Spin Columns to isolate
vBiTEs via the hexa-histidine tag. Centrifugation of columns was 2 min with open lids at 800 x g
for equilibration, washing, and elution steps and 5 min at 200 x g with closed lids following loading
with supernatant. All steps were performed at 4°C and all solutions were kept on ice. Columns
were equilibrated with 600 µL washing buffer 1 (WB1: DPBS, 200 mM sodium chloride, 10 mM
imidazole, pH 8.0) each, followed by loading with 600 µL filtered supernatant. Several columns,
six to eight in most cases, were used in parallel, depending on total volume of the collected
supernatant. Each column was loaded up to twelve times with fresh supernatant, with a washing
step with 600 µL WB1 after every third loading. After the last loading, columns were washed
three times with WB1 and once with WB2 (DPBS, 200 mM sodium chloride, 20 mM imidazole,
pH 8.0) before bound protein was eluted from the column matrix using elution buffer 5 (EB5:
DPBS, 200 mM NaCl, 500 mM imidazole, pH 7.0). For desalting and to increase concentration of
vBiTE, eluates from the same production were pooled, diluted with DPBS to a final volume of
15 mL, and transferred to Amicon Ultra-15 Centrifugal Filter Units with Ultracel-10 membranes.
Tubes were centrifuged for 10 min at 4,000 x g, flow-through was discarded and the suspension
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remaining above the membrane, containing concentrated vBiTE, was diluted to 15 mL with
DPBS again. This was repeated twice to remove residual ions from the elution buffer. By final
centrifugation for 30 min at 4,000 x g and 4°C, vBiTE suspension volumes were reduced to
approximately 200 µL. vBiTE was stored at -80°C in 10 µL aliquots for further use.
Protein quantification
Bicinchoninic acid (BCA) assay was performed using BCA Protein Assay Kit according to the
manufacturer’s instructions to determine protein concentration of vBiTE solutions. Briefly, a
two-fold dilution series of bovine serum albumin (BSA) in DPBS, starting at 2 mg/mL, was
prepared. The vBiTE samples of interest and duplicates of each BSA concentration and DPBS
alone were transferred to a 96-well plate and incubated with freshly prepared working solution
containing BCA and cupric sulfate for 30 min at 37°C. Absorption at 562 nm was then measured
using Infinite M200 microplate reader. A standard curve was calculated for the BSA dilution
series and vBiTE concentration was determined accordingly by fitting the measured absorbance
value to the standard curve.
Enzyme-linked immunosorbent assay (ELISA)
For detection of BiTE present in the supernatant of cells after inoculation with MV-BiTE, ELISA
was performed on Nunc MaxiSorp 96-well plates coated with 100 ng recombinant human CD20
full length protein in 100 µL DPBS per well at 4°C overnight. Wells were washed twice with
DPBS and blocked with 200 µL DPBS containing 5% FBS per well for 2 h at room temperature.
Wells were washed thrice with PBS before 100 µL of cell-free supernatant or medium only were
added per well and incubated for 2 h at room temperature, followed by three washing steps
with DPBS, 0.05% Tween20. 100 µL anti-HA-biotin, diluted 1:500 in DPBS containing 5% FBS,
were added to each well and incubated for 1 h at room temperature. Then, plates were washed
five times with DPBS, 0.05% Tween20 and 100 µL streptavidin-coupled horseradish peroxidase
diluted 1:500 in DPBS, 5% FBS were added to each well. After incubation for 15 min at room
temperature, plates were washed seven times with DPBS, 0.05% Tween20 and 100 µL 1-Step
Ultra TMB-ELISA Substrate Solution were applied to each well. Reaction was stopped after 30
min by adding 100 µL Stop Solution to each well and absorbance was measured at 450 nm using
Infinite M200 microplate reader. Background absorbance at 570 nm was subtracted.
Isolation of human immune cells from peripheral blood
To isolate human peripheral blood mononuclear cells (PBMCs), blood was drawn from healthy
donors into a syringe containing 123 µL 0.5 M ethylenediaminetetraacetic acid (EDTA) per 10
mL blood to prevent coagulation. Blood was diluted 1:1 with PBS, 2 mM EDTA and carefully
layered on top of 15 mL Ficoll-Paque PLUS in a 50 mL tube. After centrifugation for 30 min
at 400 x g and 20°C and without brakes, the PBMC-containing interphase between Ficoll and
serum layers was transferred to a fresh 50 mL tube using a Pasteur pipet. DPBS was added to
a final volume of 50 mL and cells were pelleted at 300 x g for 10 min. Washing was repeated
twice before cells were resuspended in 1 to 10 mL DPBS for counting using a hemacytometer
after dilution of 10 µL cell suspension in 90 µL of Trypan blue.
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Isolation of murine splenocytes and enrichment of T cells by negative magnetic selection
For isolation of murine splenocytes, mice were killed by cervical dislocation. Spleens were
explanted, transferred to 2 mL microcentrifuge tubes containing DPBS, and kept on ice. Spleens
were passed through 100 µm cell strainers into individual 50 mL tubes containing a total volume
of 10 mL DPBS. Cells were pelleted by centrifugation for 10 min at 300 x g and resuspended
in 1 mL ACK lysing buffer to remove residual erythrocytes. After 10 min incubation at room
temperature, 9 mL DPBS were added and cells were pelleted again. If red cells were still visible
in the pellet, ACK lysis was repeated for 5 min at room temperature. Cells were resuspended in
10 mL DPBS and counted.
Separation of CD3+ T cells by negative selection was performed using Pan T cell Isolation Kit
II, mouse according to the manufacturer’s instructions. Briefly, separation buffer (DPBS, 0.5%
BSA, 2 mM EDTA) was prepared and splenocytes were resuspended at 107 cells per 40 µL buffer.
Per 40 µL buffer, 10 µL Biotin-Antibody Cocktail were added, mixed, and incubated for 5 min
at 4°C. Subsequently, 30 µL buffer and 20 µL Anti-Biotin MicroBeads were added per 107 cells,
respectively. After mixing, cells were incubated for 10 min at 4°C. LS columns were equilibrated
with 3 mL buffer on a MACS Separator (Miltenyi Biotec) before cell suspension was added.
Flow-throughs of loading with cell suspension and of subsequent washing with 3 mL buffer were
collected, containing unlabeled T cells. Purified T cells were counted using a hemacytometer.
Flow cytometry-based BiTE binding assay
Binding of BiTEs to target tumor and immune cells by flow cytometry was assessed using
phycoerythrin (PE)- and fluorescein isothiocyanate (FITC)-conjugated antibodies targeting BiTE-
associated HA- and His-tags, respectively. For this, 106 cells were incubated with 1 µL Purified
Rat Anti-Mouse CD16/CD32 for mouse cells and 0.83 µL Kiovig for human cells, respectively,
to block unspecific binding to immunoglobulins, in 50 µL DPBS, 1% FBS, for 5 min at room
temperature. Indicated amounts of MV-BiTE or vBiTE, typically 3 µL, were added and cells
were incubated for 30 min on ice. Cells were washed by adding 1 mL DPBS, 1% FBS, and
centrifugation at 300 x g and 4°C for 5 min. Cells were resuspended in a total volume of 50
µL DPBS containing 1% FBS and either anti-HA-PE or anti-His-FITC antibody was added at
respective dilutions indicated in 2.1.5. After incubation for 30 min on ice, cells were washed
as before and resuspended in 500 µL DPBS contai.ning 0.2 µg/mL 4’,6-diamino-2-phenylindole
(DAPI) for. staining of dead cells. Cells were directly washed again, resuspended in 300 µL
DPBS, 1% FBS and transferred to flow tubes prior to analysis on an LSR II flow cytometer using
BD FACSDiva software. For analysis of CD20 expression, cells were incubated for 30 min on ice
once with anti-CD20-PE antibody instead of subsequent staining with BiTE and tag-specific
antibody. For all flow cytometry analyses, appropriate single stain controls were applied for
compensation and isotype controls were analyzed to control for unspecific binding by antibodies.
Flow cytometry data were analyzed using BD FACSDiva v8.0.1 (BD Biosciences) and FlowJo
VX v10.0.7r2 (TreeStar, Inc.) software.
Lactate dehydrogenase (LDH) release assay
To analyze BiTE-mediated cytotoxicity in co-cultures of target tumor and immune effector cells,
LDH release assay was performed using Promega CytoTox 96 Non-Radioactive Cytotoxicity Assay
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kit according to the manufacturer’s instructions. In brief, 40 µL PBMC medium (RPMI, 10%
FBS, 10 mM HEPES, 1% ABAM) containing 5,000 target cells (T) were added to a round-bottom
96-well plate. 40 µL PBMC medium containing 125,000 effector cells (E) were added for an
E:T-ratio of 50:1. 20 µL PBMC medium containing vBiTE suspension were added to achieve
indicated final concentrations. Each sample and control was prepared in triplicates. Controls
containing medium only, target cells only (Tsp), and effector cells only (Esp) were included. For
target cells only and medium only, additional controls were included for assessing maximum
target cell (Tmax) lysis by addition of detergent and the appropriate volume control, respectively.
Plates were incubated at 37°C for 24 h in case of human PBMCs as immune effector cells and for
48 h for murine T cells. 10 µL of 10x lysis solution were added to each well containing maximum
target cell lysis and volume controls, respectively, and incubation was continued for 45 min.
Successful cell lysis was verified by light microscopy. Plates were then centrifuged for 4 min at
250 x g and 50 µL of cell-free supernatants were transferred carefully to a clean flat-bottom
96-well plate. To each well, 50 µL of freshly prepared substrate solution were added and plates
were incubated for approximately 30 min at room temperature, until maximum lysis controls
had turned deep red. Reaction was stopped by addition of 50 µL stop solution to each well. Air
bubbles were removed by centrifugation for 1 min at 4,000 x g and absorbance was measured at
490 nm using Infinite M200 microplate reader. Background correction for Tmax samples was
performed by subtracting average value of volume controls. For all other samples and controls,
the average absorbance of medium controls was subtracted. Average values were calculated for
background-corrected Tmax, Tsp, and Esp values, and % specific lysis was calculated for each
sample using the following equation: % specific lysis = sample value−Tsp−EspTmax−Tsp x100.
Ultraviolet C (UV) inactivation of MV-BiTE
UV irradiation of MV-BiTE was performed using UV Stratalinker 2400 (Stratagene). For
complete inhibition of viral replication, 2x107 ciu MV-BiTE diluted in 2 mL Opti-MEM in a 2
mL microcentrifuge tube were irradiated at a dose of 1.5 J/cm2 (cUV). For partial inhibition,
the same dose was applied to a 1.5 microcentrifuge tube containing 500 µL undiluted virus
suspension.
2.2.2 MV-BiTE in vivo
Animal experimentation
All animal experiments performed in the course of my doctoral studies in Heidelberg were approved
by the Animal Protection Officer at the German Cancer Research Center (DKFZ) and by the
regional council according to the German Animal Protection Law. In general, mice were kept in
groups of five or less in specific pathogen-free individually ventilated cages with permanent access
to enrichment, food, and drinking water in the Center for Preclinical Research of the DKFZ. For
subcutaneous and intratumoral injections, 1 mL syringes and hollow 26 G needles were used.
After tumor implantation, mice were checked daily for signs of illness, tumor diameters were
assessed every two to three days by caliper measurement, and mouse weights were measured once
weekly. Termination criteria resulting in immediate sacrifice of the respective animal were defined
as tumor volume (calculated by largest diameter x smallest diameter² x 0.5) > 1000 mm³, tumor
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diameter > 15 mm, tumor ulceration, weight loss of > 20% within one week, or other signs of
severe illness such as ill-kempt fur, hunched posture, heavy breathing, or apathy.
Tumor model
For analysis of MV-BiTE in vivo, 1x106 B16-CD20-CD46 cells of low passage number were washed
twice with DPBS, resuspended in 100 µL DPBS, and injected subcutaneously into the right
flank of six- to eight-week-old female C57BL/6 mice. Treatment was initiated when tumors had
reached average volumes of 35-40 mm³ for survival experiments and 60-70 mm³ for mechanistic
analyses. Mice were stratified into treatment groups to achieve similar distribution of tumor
sizes and similar average volumes per group. After stratification, the experimenter was blinded
to intervention until the experiment ended, including during treatments, tumor measurements,
and sample analyses. Mice were treated by five intratumoral injections with indicated viruses or
control treatments on consecutive days.
MV immunization and serum neutralization assay
Prime-boost vaccination of naïve C57BL/6 mice was performed 16 and 9 days prior to tumor
implantation, respectively. At both time points, animals received intraperitoneal injections of
1x106 ciu of highly purified MV-NIS. A previously described in vitro neutralization assay155 was
performed with minor modifications to confirm presence of neutralizing antibodies against measles
virus in the blood of immunized mice before start of the survival experiment. From the saphenous
veins of pre-immunized and naïve control mice, blood was drawn into heparin-coated tubes and
centrifuged for 10 min at 10,000 x g and 4°C for serum isolation. Sera were transferred to clean
microcentrifuge tubes and heat inactivated by incubation in a 56°C water bath for 30 min. In
a 96-well plate, 20 µL of serum were added to the wells of the first column containing 80 µL
Opti-MEM to achieve a five-fold dilution. After mixing by pipetting, serial two-fold dilutions were
prepared by transferring 50 µL from each well to the next column containing 50 µL Opti-MEM
per well. When finished, 50 µL were discarded from each well of the last row to equalize volumes.
Subsequently, 50 µL Opti-MEM containing 50 ciu of unmodified MV were added to each well and
incubated for 1 h at 37°C, 5% CO2. Next, 2x104 Vero cells in 100 µL DMEM were added to each
well and incubation was continued for 72 h at 37°C, 5% CO2 before presence of syncytia was
assessed via light microscopy.
Ex vivo analysis
For survival analyses, tumor growth was followed until termination criteria were reached. For
mechanistic analyses, mice were sacrificed at indicated time points, i.e. one day after the last
treatment for flow cytometry, reverse transcription quantitative real time polymerase chain
reaction (RT-qPCR) analysis of FoxP3 and T-bet expression, and targeted transcriptome analyses
and directly after the first and the last treatment and one, two, and five days after the last
treatment, respectively, for time course analysis of MV-N and BiTE expression.
Subcutaneous tumors were explanted and partitioned using a scalpel. Tumor samples to be
analyzed by flow cytometry on the same day were kept in DPBS on ice, and for RNA analyses in
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RNAlater RNA Stabilizing Reagent for up to seven days at 4°C, then transferred to -20°C in case
of longer storage.
For flow cytometry analysis, single cell suspensions were prepared by passing tumors through
100 µm cell strainers into 50 mL tubes containing 10 mL DPBS. Cells were counted as described
above and 2x106 cells per sample were resuspended in 100 µL DPBS, 1% FBS and incubated
subsequently with mouse Fc block, specific antibodies, and DAPI as described above. Single
stain controls, isotype controls, and fluorescence minus one (FMO) controls were prepared for
compensation and gating. Samples were analyzed in 300 µL DPBS, 1% FBS, in flow tubes on a
BD LSR II cytometer.
For RT-qPCR and targeted transcriptome analysis, total RNA was isolated from tumors using
Qiagen RNeasy Mini Kit according to the manufacturer’s instructions. All steps were carried
out at room temperature. In brief, 30 mg tumor samples were disrupted in 600 µL Buffer RLT
in 1.5 mL microcentrifuge tubes with a pestle (schuett-biotec), followed by homogenization.
For this, tumor samples were loaded onto QIAshredder homogenizer columns placed in 2 mL
microcentrifuge tubes and centrifuged for 2 min at 16,000 x g. Columns were removed and tubes
were centrifuged for 3 min at 16,000 x g. Supernatants were transferred to clean tubes and
an equal volume of 70% ethanol was added. Samples were mixed by pipetting up and down,
transferred to RNeasy spin columns on 2 mL collection tubes, and centrifuged at 8,000 x g for
15 s. Flow-throughs were discarded and columns were washed thrice by adding 700 µL Buffer
RW1 once and 500 µL Buffer RPE twice, with centrifugation steps as before and discarding
of flow-throughs in between. The last washing step was performed with centrifugation for 2
min at 8,000 x g, followed by 1 min at 8,000 x g in a fresh collection tube to eliminate residual
RPE buffer. RNA was eluted in 30 µL RNase-free H2O into a clean 1.5 mL collection tube by
centrifugation for 1 min at 8,000 x g.
Complementary DNA (cDNA) was synthesized from mRNA using the Maxima H Minus First
Strand cDNA Synthesis Kit according to the manufacturer’s instructions. Briefly, 500 ng RNA
were mixed with 100 pmol of oligo(dT)18 primers and 1 µL dNTP mix containing 10mM of each
dATP, dGTP, dCTP, and dTTP in a final volume of 14.5 µL nuclease-free H2O. 4 µL 5x RT
Buffer, 0.5 µL RiboLock RNase Inhibitor, and 200 U Maxima H Minus Reverse Transcriptase
were added to a final volume of 20 µL. The reaction mix was mixed carefully by flicking the tube,
centrifuged shortly to collect all liquid at the bottom of the tube, and incubated for 30 min at
50°C. The product containing cDNA was then stored at -20°C until further processing.
qPCR reactions were set up in triplicates in LightCycler 480 Multiwell Plate 96 plates containing
1 µL of cDNA synthesis product, each primer of the respective target-specific primer pair at a
final concentration of 0.2 µM, and 10 µL Power SYBR Green PCR Master Mix in a final volume
of 20 µL per well. Control samples without template and of reverse transcription reaction mixes
lacking reverse transcriptase were included for each run. Reactions were performed on a cobas z
480 instrument. Each run started with an initial denaturation step for 10 min at 95°C. Forty
cycles followed, consisting of denaturation for 5 s at 95°C, annealing and extension for 1 min
at 55°C (for T-bet), 60°C (for BiTEs, FoxP3, and L13a), or 62°C (for MV-N), and fluorescence
detection for 5 s at 77°C (for T-bet, FoxP3, and L13a), 78°C (for MV-N), 80°C (for mCD3xCEA
BiTE), or 84°C (for mCD3xCD20 BiTE). Data analysis was performed using LightCycler 480
Software version 1.5.
For targeted transcriptome analysis using NanoString nCounter technology156, RNA samples
containing 100 ng RNA in 1 µL H2O were prepared and submitted to the nCounter Core Facility
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Heidelberg for further processing. RNA quality was assessed using Agilent Bioanalyzer 2100 and
Qubit system and 25 ng RNA per sample were hybridized with the Mouse CodeSet Immunology
Panel. Hybridized RNA was quantified on nCounter SPRINT Profiler and data was obtained
from the nCounter Core Facility. Data was analyzed using nSolver 4.0 software and Advanced
Analysis package after normalization of raw data to a pre-defined set of reference genes included
in the Mouse CodeSet Immunology Panel.
2.2.3 CAR T cell methods
Production of retroviral vectors
Chimeric antigen receptor (CAR)-encoding retroviral vectors for transduction of human T cells
were produced by transient transfection of 293GP cells. For this, 6x106 cells were seeded in 10
mL DMEM, 10% FBS on a 10 cm dish and incubated overnight at 37°C, 5% CO2. The next day,
1.5 mL Opti-MEM containing 4.5 µg plasmid encoding RD114 envelope protein (pLTR-RD114A)
and 9 µg CAR-encoding transfer plasmid (pMSGV1-Ha1-4.117scFv-28Z for second generation or
pMSGV1-Ha1-4.117scFv-28-BBZ for third generation anti-PSCA CAR) and 1.5 mL Opti-MEM
containing 60 µL Lipofectamine 2000 transfection reagent were prepared in 15 mL tubes and
incubated separately for 5 min at room temperature. After transferring the plasmid-containing
mix into the tube containing the transfection reagent and pipetting up and down once, the final
transfection mix was incubated for 20 min at room temperature. During incubation, medium
on the 293GP cells was replaced with 10 mL of fresh DMEM, 10% FBS. The transfection mix
was carefully added dropwise to the cells to avoid mechanic detachment. After incubation for
6-8 h at 37°C, 5% CO2, medium on the cells was replaced with 10 mL DMEM, 10% FBS, 1%
penicillin/streptomycin solution (Pen/Strep) and incubation was continued. Forty-eight hours
post transfection, supernatant was harvested, passed into a 15 mL tube through a 0.45 µm filter
using a syringe, and stored at -80°C. Ten milliliters of fresh DMEM, 10% FBS, 1% Pen/Strep
were added to the cells and incubation was continued for 24 h before supernatant was harvested,
filtered, and stored as before.
Retroviral transduction of human T cells
Human PBMCs were derived from peripheral blood as described in 2.2.1 and resuspended at
1x106 cells/ mL in X-VIVO 15 medium supplemented with 5% human serum, 1% anti-biotic/anti-
mycotic solution (ABAM), and 50 IU/ mL IL-2 (from here on referred to as T cell medium, TCM).
To a non-tissue culture-treated (NTC) 24-well plate, 1 mL medium containing cells was added
per well. Cells were stimulated by adding 0.5 µg/mL OKT3 antibody, followed by incubation for
two days at 37°C, 5% CO2. On day two post stimulation, two NTC 6-well plates were prepared
for transduction by incubation with 1.5 mL DPBS containing 20 µg/ mL RetroNectin per well
for each virus construct for 2 h at room temperature. Subsequently, RetroNectin solution was
removed and stored at -20°C to be re-used up to three times. Plates were blocked for 30 min
at room temperature with 2 mL DPBS, 2% bovine serum albumin (BSA) per well. Following
removal of BSA solution, wells were washed with 2 mL DPBS, and 2 mL of filtered supernatant
from retrovirus production were added to the respective wells. Both plates were centrifuged at
2,000 x g and 32°C for 2 h. One plate was used directly for transduction and the other one was
stored at 4°C in an autoclaving bag overnight for a second transduction on the following day.
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For transduction, stimulated T cells were pooled from the 24-well plate, counted, and resuspended
at 5x105 cells/ mL in fresh TCM. To designated wells on the prepared 6-well plate, 4 mL of cell
suspension, i.e. 4x106 cells per well, were added. Excess cell suspension was cultured in a T25
NTC flask as untransduced T cell control (UT). In general, T cells were sub-cultured twice a
week and kept at densities between 3x105 and 3x106 cells per mL. The plate containing cells and
virus was centrifuged for 10 min at 1,000 x g and 32°C to collect the cells at well bottoms and
subsequently incubated at 37°C, 5% CO2 overnight. The next day, cells were transferred to the
previously prepared plate to increase transduction efficiency. Cells were collected at the bottom
of the wells as before and again incubated at 37°C, 5% CO2 overnight. Following transduction,
on day four post stimulation, cells were transferred from the 6-well plate to 15 mL tubes, spun
down for 5 min at 300 x g, resuspended at 1x106 cells/ mL in fresh TCM, and incubated in NTC
cell culture flasks at 37°C, 5% CO2.
Flow cytometry analysis of CAR expression by human T cells
Three days after transfer of transduced cells to culture flasks and directly before use in an
experiment, CAR expression by human T cells was analyzed via flow cytometry using Protein L,
which binds immunoglobulin light chains, including unstained, single-stained, and UT samples as
controls. For this, 2x105 cells per sample were washed twice with DPBS, 2% BSA to remove residual
TCM, which would interfere with staining using Protein L due to presence of immunoglobulins in
human serum. All centrifugation steps were performed at 300 x g and 4°C for 5 min. Cell were
then incubated with 1 µL Protein L-Biotin in a total volume of 300 µL DPBS, 2% BSA for 30
min on ice. After washing twice with DPBS, 2% BSA, Protein L-bound cells were stained with 1
µL streptavidin in 100 µL DPBS for 30 min on ice. Cells were then washed once with DPBS,
2% BSA, resuspended in 500 µL DPBS, 2% BSA, 0.2 µg/ mL DAPI, and acquired in flow tubes
using a BD LSR II flow cytometer.
Impedance-based cell viability assay
CAR T cell-mediated cytotoxicity was analyzed using impedance measurement via the xCELLi-
gence RTCA MP system (ACEA Biosciences Inc.) as a surrogate for viability of adherent target
cells. For this, following a background measurement with 50 µL medium only per well, 1x104
human pancreatic adenocarcinoma (HPAC) cells or PC05 cells in 50 µL cell type-specific medium
per well were added to an appropriate 96-well plate, placed in the instrument, and incubated
overnight at 37°C, 5% CO2 to allow attachment to the well bottom. The next day, 10 µL TCM
or indicated virus suspensions were added to respective wells and incubated at 37°C, 5% CO2 for
2 h. All samples were set up in three technical replicates. Following incubation, 90 µL TCM or
indicated T cell suspensions were added to the respective wells and incubation was continued for
three to five days. Impedance measurements were performed automatically every five minutes,
starting directly after cell seeding and paused when plates were taken out to add virus or effector
cells, and values were normalized to the time point after last addition to the wells.
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In vivo analysis of MV and CAR T cell combinations
A pilot experiment investigating combination treatments of intratumoral MV or MV-BiTE
application with adoptive transfer of UT or CAR T cells in immunodeficient mice bearing
human xenograft tumors was performed at H. Lee Moffitt Cancer Center and Research Institute,
Tampa, FL, USA in the course of my research visit in Dr. Daniel Abate-Daga’s laboratory. All
experimental procedures were approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of South Florida. Mice were housed under specific pathogen-free
conditions in accordance with IACUC standards at the H. Lee Moffitt Cancer Center and Research
Institute. 2x106 HPAC cells were implanted subcutaneously in six- to eight-week-old female
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice obtained from The Jackson Laboratory (Bar
Harbor, ME, USA). When tumors had reached an average volume of 40 mm³, they were treated
by intratumoral injections of 1x106 unmodified MV or MV encoding CEA-targeting BiTE (MV-
hCD3xCEA) or medium only in a volume of 100 µL on four consecutive days. One day later,
mice received 1x106 PSCA2 CAR-expressing human T cells or the corresponding amount of
untransduced T cells in 100 µL DPBS via tail vein injection by expert staff of the animal facility
at Moffitt. Mice treated with T cells received 2.2x105 IU recombinant human IL-2 in 200 µL
DPBS intraperitoneally on the day of T cell injection and the two following days, respectively.
Tumor volumes were measured every two to three days and animals were sacrificed 30 days post
T cell transfer to prevent potential onset of graft-versus-host disease. Throughout the experiment,
animals were monitored every day and no signs of illness were observed. Spleens were explanted,
single cell suspensions of splenocytes were prepared and analyzed for human CD3 expression by
flow cytometry as described in 2.2.1.
T cell labeling with iron oxide nanoparticles
Human T cells obtained from human peripheral blood and stimulated as described above (2.2.3)
were labeled with superparamagnetic iron oxide nanoparticles CLIO-FITC or ferumoxytol∗ in
NTC 24-well and 6-well plates, respectively. For labeling with CLIO-FITC to be analyzed via
flow cytometry, 1x106 cells in 250 µL RPMI, 10 ng/mL IL-2 were used per well. For ferumoxytol
labeling and later magnetic resonance imaging (MRI), 4x106 cells in 1 mL medium were used.
Heparin was added to a final concentration of 20 IU/mL and mixed by gentle swirling of the
plate. Next, protamine sulfate was added at a final concentration of 30 µg/mL, or of 60 µg/mL
for comparison, followed by swirling the plate, before nanoparticles were added to a final iron
concentration of 100 µg/mL. After swirling the plate, cells were incubated for 4 h at 37°C, 5% CO2
before an equal volume of RPMI, 10 ng/mL IL-2, 20% FBS was added to each well. Incubation
was continued overnight. Cells were then collected, washed once with DPBS and twice with
DPBS, 10 IU/mL heparin, and resuspended in 300 µL DPBS, 0.2 µg/mL DAPI in a flow tube
for analysis using an LSR II flow cytometer, or in 50 µL DPBS for 3D T2*-weighted MRI in
a capillary phantom using a 9.4T small animal imaging system (BioSpec94/20 USR, Bruker
BioSpin MRI GmbH)†.
∗both kindly provided by Dr. Dr. Michael Breckwoldt, Heidelberg University Hospital
†performed by Manuel Fischer, Heidelberg University Hospital
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2.2.4 Statistical analyses
All statistical analyses were performed using GraphPad PRISM software version 6.04 (GraphPad
Software). For statistical analyses of column data with one independent variable, one-way ANOVA
was performed and p values were adjusted for multiple comparisons by Tukey test. Two-way
ANOVA with p values adjusted for multiple comparisons by Sidak test was used to statistically
analyze grouped data with two independent variables. Statistical comparisons of Kaplan-Meier
survival curves were conducted using Mantle-Cox log-rank test with adjustment of p values for
multiple comparisons via Bonferroni correction.
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The hypothesis underlying the present study is that efficacy of T cell re-direction immunotherapies
against solid tumors can be enhanced by combination with oncolytic measles virotherapy. We
furthermore hypothesized local antitumor activity of bispecific T cell engagers (BiTEs) encoded
by oncolytic measles viruses (MV). To test these hypotheses, in the first part of the project, a
novel syngeneic murine tumor cell line expressing human antigens allowing for measles virus entry
and BiTE binding was generated, as well as BiTE-encoding MV (MV-BiTE) vectors. Kinetics
of MV-BiTE replication and cytotoxicity were analyzed in vitro and binding specificities and
functionality of virus-encoded BiTEs were investigated. MV-BiTE efficacy in vivo was assessed
by survival and mechanistic analyses in immunocompetent mice using the novel solid tumor
model.† In the second part of the project, the expression of chimeric antigen receptors (CARs) by
T cells as an alternative strategy to re-direction via BiTEs was investigated. Combinations of MV
with CAR-expressing human T cells were investigated in vitro and in an adoptive cell transfer
experiment in immunodeficient mice bearing human cancer xenografts. T cell labeling with iron
oxide nanoparticles was developed for in vivo monitoring by magnetic resonance imaging. Finally,
a mathematical model describing dynamics of MV and T cell re-direction combination therapies
was designed for future in silico experimentation to help identify parameters crucial for treatment
success and thus guide further research.
3.1 in vitro analyses of MV-BiTE
3.1.1 Generation of recombinant MV-BiTE
Oncolytic measles vaccine virus (MV) genomes encoding bispecific T cell engagers (BiTEs) for
re-direction of T cells to tumor surface antigens were designed and generated prior to start of my
PhD studies. This thesis focuses on viruses encoding BiTEs that target CD20-expressing tumor
cells‡. Unmodified MV and vectors encoding BiTEs against carcinoembryonic antigen (CEA)§
were used for control purposes throughout the present study.
Viruses with BiTE specificity for human and murine CD3 were generated using scFv sequences
derived from clones OKT3 and 145-2C11, respectively. BiTE inserts preceded by Kozak and
immunoglobulin kappa leader sequences were introduced into the additional transcription unit
(ATU) downstream of the H open reading frame and contained sequences encoding influenza
hemagglutinin peptide and hexa-histidine tags (Fig. 5).
3.1.2 Generation of a tumor model susceptible for MV-BiTE
To test anti-tumor efficacy of MV-BiTE in a syngeneic solid tumor model, murine melanoma cells
stably expressing human antigens for BiTE binding and viral entry were generated. Parental
B16 cells and B16 cells stably expressing the BiTE target antigen human CD20143 (B16-CD20)
†Main findings of the present thesis and of Dr. Tobias Speck’s dissertation have been published together150.
‡These viruses were cloned in the course of my master’s thesis project149.
§generated and analyzed by Tobias Speck151
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Figure 5: Schematic representation of BiTE-encoding oncolytic measles virus (MV-
BiTE) genome. An additional transcription unit (ATU) downstream of the H open reading
frame (ORF) within the measles virus genome (upper panel) was used to insert bispecific T cell
engager (BiTE)-encoding sequences via the reverse genetics system. The inserts include Kozak
and Immunoglobulin kappa leader (Igκ) sequences preceding the BiTE-encoding sequence for
efficient translation and secretion, respectively, and BiTE-associated protein tags for purification
and detection purposes (lower panel, shown exemplarily for CD20-targeting BiTE). HA – influenza
hemagglutinin peptide tag, VH – variable heavy chain, VL – variable light chain, G4S – flexible
peptide linker (four glycines followed by one serine), His – hexa-histidine tag.
were transduced with lentiviruses encoding the measles virus entry receptor human CD46 isoform
BC1157, followed by single cell sorting of CD46-positive clones (Fig. 6A). The cell lines B16-CD46
and B16-CD20-CD46 were established from clonal colonies #4 and #2D, respectively, which
exhibited similar duplication times compared to parental cell lines and were selected according to
CD46 expression and MV susceptibility (Fig. 6B). Forty-eight hours post inoculation with an
MV encoding enhanced green fluorescent protein (MV-ld-eGFP-H-mCD3xCD20), formation of
large, fluorescent, multinucleated syncytia was observed for B16-CD20-CD46 cells in contrast to
B16-CD20 cells. Following inoculation at a multiplicity of infection (MOI) of 1, few B16-CD20-
CD46 cells remained at the plate bottom due to cell lysis, while for an MOI of 0.1, a dense layer
of infected and uninfected cells was observed, indicating MOI-dependent MV susceptibility of the
cell line.
3.1.3 MV-BiTE kinetics in vitro
MV-BiTE viruses were successfully rescued and propagated. Kinetics of viral replication and
tumor cell lysis were determined for Vero producer cells and murine B16 cell lines by one-step
growth curve infection experiments and XTT cell viability assays, respectively, and compared to
unmodified virus (Fig. 7A,B). Viral progeny titers obtained from Vero cells peaked between 105
and 106 cell infectious units (ciu)/mL between 24 and 36 h after inoculation with unmodified
oncolytic measles virus (MV) or MV encoding BiTEs targeting human (h) or murine (m) CD3
and CD20 or CEA (MV-hCD3xCD20, MV-hCD3xCEA, MV-mCD3xCD20, MV-mCD3xCEA,
respectively). Correspondingly, Vero cell viability relative to uninfected (mock) decreased rapidly
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Figure 6: Generation of a murine melanoma cell line stably expressing human CD46
for measles virus entry. A. Flow cytometry analysis with phycoerythrin (PE)-labeled anti-
CD46 antibody. Upper panel - general gating strategy shown for unstained sample of B16
cells incubated with DAPI. Lower panel – CD46 expression of selected samples. From left to
right: B16 cells transduced with CD46-encoding lentiviral vector (LV-CD46) (“B16-CD46 bulk”),
clonal cell line obtained after single cell sorting for CD46 expression (“B16-CD46 clone #4”),
B16 cells stably expressing human CD20 antigen (“B16-CD20”), and a single cell clone selected
for CD46 expression from B16-CD20 cells transduced with LV-CD46 (“B16-CD20-CD46 clone
#2D”). B. MV susceptibility of B16-CD20 cells stably expressing human CD46. CD46-negative
B16-CD20 cells and B16-CD20-CD46 clones expressing human CD46 as verified by flow cytometry
were inoculated with eGFP-encoding MV at indicated multiplicities of infection (MOIs). eGFP
expression was analyzed 48 h post inoculation. Shown are fluorescence microscopy and phase
contrast images for B16-CD20 cells and the most susceptible B16-CD20-CD46 clone 2D.
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Figure 7: MV-BiTE replication and cytotoxicity kinetics in vitro. Indicated cell types
were inoculated with medium only (mock) or indicated viruses at a multiplicity of infection of 1.
For one-step growth curve experiments, cells were scraped into the supernatant at indicated time
points viral progeny titers were determined by titration assay on Vero cells (A, C, D). XTT assay
was performed to analyze virus-mediated cytotoxicity (B, E).
between 12 and 36 h post inoculation, with only minor differences between viruses. For B16-
CD20 cells not expressing the MV receptor CD46, inoculation with MV, MV-mCD3xCD20, and
MV-mCD3xCEA, respectively, yielded lower titers for each time point, with maxima around
103 ciu/mL at 12 and 48 h post inoculation. B16-CD20 cell viability was stable over 96 h post
inoculation, at approximately 150, 100, and 50 % of mock for MV-mCD3xCD20, MV, and MV-
mCD3xCEA, respectively. For both B16-CD46 and B16-CD20-CD46, progeny titers of MV and
MV-mCD3xCEA peaked around 105 ciu/mL after 36 h, and relative cell viability dropped close to
0% after 72 h. MV-mCD3xCD20 reached similar maximal progeny titers after 48 h and induced
reduction in cell viability to approximately 50 % after 72 h. In further experiments on Vero cells
(Fig. 7C), human mantle cell lymphoma Granta-519 cells (Fig. 7D), and B16-CD20-CD46 cells
(Fig. 7E), only minor differences between MV-mCD3xCD20 and other viruses were observed.
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3.1.4 Functionality of MV-encoded BiTEs
BiTEs were isolated and purified by affinity exchange chromatography as described∗ from
supernatants of MV-BiTE-infected Vero cells (henceforth referred to as virus-derived BiTEs,
vBiTEs), yielding approximately 1-3 µg protein per mL supernatant. Binding of vBiTEs to
target antigen-expressing cells was analyzed by flow cytometry. More than 95 % of human
mantle cell lymphoma Granta-519 cells, which express high levels of endogenous CD20, were
PE-positive after incubation with anti-CD20 antibody or mCD3xCD20 vBiTE followed by PE-
conjugated anti-HA tag antibody (Fig. 8A). 22.5 % of B16-CD20-CD46 cells were PE-positive
after subsequent incubation with hCD3xCD20 and anti-HA-PE antibody, while only background
binding of hCD3xCD20 vBiTE to parental B16 cells was detected (0.36 % PE-positive) (Fig. 8B).
vBiTE binding to immune effector cells was analyzed using FITC-labeled anti-His tag antibody†
(Fig. 8C). Approximately 40 % of murine splenocytes were bound by vBiTEs specific for murine
CD3 (mCD3xCD20, mCD3xCEA), in contrast to hCD3-targeting vBiTEs hCD3xCD20 and
hCD3xCEA (1,71 and 1,88 % FITC-positive, respectively). After incubation with hCD3xCEA
vBiTE, FITC signals were detected for 57.1 % of human peripheral blood mononuclear cells
(PBMCs), compared to 1.21 % observed for mCD3xCEA. For CD20-specific vBiTEs, the values
were approximately 10 % higher (71.9 % and 9.8 % for hCDxCD20 and mCD3xCD20, respectively).
These results indicate antigen-specific cell binding by vBiTEs.
vBiTE functionality was assessed in co-cultures of tumor cells and immune effector cells via lactate
dehydrogenase release assay. After 24 h, approximately 50 % specific lysis of B16-CD20‡ and
B16-CD20-CD46 cells was achieved in the presence of 100 and 500 ng/mL hCD3xCD20 vBiTE
obtained from independent Vero cell infections and subsequent purifications, respectively (Fig.
9A). Compared to parental B16 cells not expressing the BiTE target antigen CD20, significantly
higher lysis was observed at vBiTE concentrations of 1 and 0.5 ng/mL, respectively, and above.
For Granta-519 cells, between 80 and 100 % specific lysis was observed for hCD3xCD20 vBiTE
concentrations of 10 to 1000 ng/mL in presence of PBMCs, which was significantly higher
compared to mCD3xCD20 control vBiTE. Specific lysis of B16-CD20-CD46 cells co-incubated
with murine T cells increased with mCD3xCD20 vBiTE concentration (Fig. 9B). In three
experiments with independently produced vBiTE samples, around 15 % specific lysis was achieved
at vBiTE concentrations of 1 µg/mL. At 100 ng/mL, lysis was also significantly higher compared to
B16-CD46 cells not expressing CD20. This indicates vBiTE concentration-dependent induction of
surface antigen-specific tumor cell lysis by resting, polyclonal immune cells and thus functionality
of virus-encoded BiTEs.
3.1.5 Preparation of appropriate controls for in vivo experimentation
Due to generation of MV-BiTE from crude cell lysates, BiTEs expressed by infected cells during
virus production were present in virus suspensions, requiring appropriate controls for assessing
efficacy in vivo. Therefore, the BiTE level present in virus suspension was assessed by vBiTE
titration on Granta-519 cells, which express high levels of endogenous CD20. In a final volume
of 50 µL, cells were incubated with 10 µL OptiMEM containing 1x105 ciu MV-mCD3xCD20,
∗established during master’s thesis work149 and published in a video protocol in the course of my doctoral
project134
†experiment performed during my master’s thesis work149
‡experiment performed during my master’s thesis work149
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A
B
C
Figure 8: Binding of MV-encoded BiTEs to target cells in vitro. BiTEs were purified
from the supernatant of MV-BiTE-infected Vero cells (vBiTEs) and binding to target cells was
determined via flow cytometry using fluorophore-labeled antibodies specific for BiTE-associated
peptide tags. PE – phycoerythrin, FITC – fluorescein isothiocyanate. A. Binding of mCD3xCD20
vBiTE to human mantel cell lymphoma cells (Granta-519). Endogenous CD20 expression was
verified using PE-conjugated anti-human CD20 antibody (right panel). B. Binding of hCD3xCD20
vBiTE to murine melanoma cells expressing human antigens (B16-CD20-CD46). Parental B16
cells not expressing human antigens served as negative control (right panel). C. Binding of vBiTEs
of different specificities to human (top) and murine (bottom) immune cells. PBMCs – peripheral
blood mononuclear cells.
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Figure 9: BiTE-mediated cytotoxicity in vitro. Indicated target tumor cells were co-
incubated with (A) unstimulated human peripheral blood mononuclear cells (PBMCs) or (B)
primary murine T cells for 24 and 48 hours, respectively, at effector-to-target cell ratios of 50:1.
Relative target cell lysis in the presence of vBiTEs at indicated concentrations was determined
by LDH release assay. Cells not expressing the relevant vBiTE target antigen (left and middle
panels in the top row and all panels in the bottom row) or vBiTE of irrelevant specificity (upper
right panel) served as controls. Shown are means ± standard deviation. Two-way ANOVA was
performed for statistical analysis and p values were adjusted for multiple comparisons using Sidak
test.
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corresponding to a titer of 1x107 ciu/mL, or different concentrations of mCD3xCD20 vBiTE
and binding was determined by flow cytometry. For the mCD3xCD20 vBiTE concentration of
21.725 µg/mL, observed binding was comparable to the virus sample (Fig. 10A). Accordingly,
the amount of BiTE present in one MV-mCD3xCD20 dose for in vivo treatment, i.e. 100 µL at a
titer of 1x107 ciu/mL, corresponds to approximately 2.17 µg vBiTE.
To dissect potential mechanisms of action, we tested an approach to inhibit replicative potential
of MV-BiTE while maintaining a suspension of similar composition and BiTE level. To achieve
this, the impact of ultraviolet (UV) C irradiation on viral replication and BiTE binding was
assessed by titration assay and flow cytometry analysis of irradiated MV-BiTE samples in parallel.
UV doses of 0.25 and 0.5 J/cm² resulted in titer reduction by five orders of magnitude and in
complete abrogation of viral replication, respectively, while mean fluorescence intensity of signals
detected in the flow cytometry-based BiTE binding assay with Granta-519 cells was reduced by
approximately 10 and 20 % (Fig. 10B). This indicates feasibility of UV irradiation at a dose that
completely inhibits viral replication without abrogating BiTE binding.
In order to assess the impact of viral replication on treatment outcome in vivo, irradiation
schedules were adjusted to achieve viral titer reduction of two orders of magnitude (partial UV
inactivation, pUV) and complete abrogation of viral replication (complete UV inactivation, cUV),
respectively. Replication kinetics were analyzed on B16-CD20-CD46 cells by a one-step growth
curve experiment (Fig. 10C). Cells were inoculated with MV-mCD3xCD20 at a multiplicity of
infection of 1 and respective amounts of pUV- and cUV-treated virus. Viral progeny titers were
measured at indicated time points by titration assay on Vero cells. Progeny titers peaked at 48
h post inoculation with MV-mCD3xCD20 between 2x104 and 4x104 ciu/mL. pUV-irradiated
samples only yielded detectable progeny of approximately 1x102 and 2x102 ciu/mL at 48 and 72
h post inoculation, respectively, while no infectious progeny was detected after cUV irradiation.
These results confirm partial and complete inhibition of viral replication by pUV and cUV
irradiation schedules, respectively. Therefore, these schedules were used to prepare controls for
subsequent in vivo studies.
For comparison of BiTE expression kinetics, de novo BiTE synthesis by Vero cells and B16-CD20-
CD46 cells following inoculation with MV-mCD3xCD20 in vitro was monitored by ELISA of
cell-free supernatants (Fig. 10D). For both cell lines, relative BiTE levels reached a maximum
of 4-fold over medium after 72 h before decreasing to approximately 2-fold at 96 h. When
inoculated with pUV- or cUV-inactivated virus, no increase in BiTE levels in the supernatant
of B16-CD20-CD46 cells was observed, indicating absence of de novo synthesis of MV-encoded
BiTEs in the tumor model in vitro upon UV irradiation, even at a dose that still allows for
reduced viral replication.
3.2 Anti-tumor efficacy of MV-BiTE in immunocompetent mice
3.2.1 Tumor growth in vivo
To assess therapeutic efficacy of MV-BiTE treatment, C57BL/6 mice bearing subcutaneous
B16-CD20-CD46 tumors received intratumoral injections of carrier fluid, vBiTE, control viruses,
MV-BiTE, or UV-irradiated MV-BiTE, respectively, on five consecutive days. Tumor growth in
individual mice was measured in three independent experiments (Fig. 11A-C). For mice receiving
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Figure 10: Effects of UV-C irradiation on MV-BiTE in vitro. A. Titration of vBiTE
versus MV-BiTE suspension. Granta-519 cells were inoculated with 10 µL of OptiMEM containing
1x105 ciu MV-BiTE or indicated volumes of mCD3xCD20 vBiTE. Binding of BiTEs present in the
viral suspension and purified vBiTE was determined using a phycoerythrin (PE)-labeled antibody
targeting BiTE-associated HA-tag. B. Effects of ultraviolet C (UV-C) radiation on MV-BiTE
titers and BiTE binding. Viral suspension of MV encoding mCD3xCD20 BiTE was irradiated
at indicated intensities. Viral titers were assessed by titration assay (left y-axis on left panel)
and binding of BiTEs to Granta-519 cells was analyzed with anti-HA-PE antibody (right y-axis
and right panel). MFI – mean fluorescence intensity, au – arbitrary units. C. Effect of UV-C
irradiation on MV-BiTE replication. B16-CD20-CD46 cells were inoculated with MV-BiTE at a
multiplicity of infection of 1 and equal amounts of viral suspensions previously irradiated at two
different intensities to achieve partial (pUV) or complete (cUV) inactivation. Viral progeny titers
were assessed at indicated time points by titration assay on Vero cells. D. Effect of MV-BiTE
irradiation on de novo production of BiTEs. Vero or B16-CD20-CD46 cells were inoculated with
mCD3xCD20-encoding MV at a multiplicity of infection of 1 or equal amounts of partially (pUV)
or completely (cUV) inactivated virus suspension as indicated. At indicated time points, cell-free
supernatants were harvested and levels of CD20-specific BiTE were assessed by ELISA. Values
were normalized to medium only (mock).
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Figure 11: Effect of MV-BiTE treatment on tumor growth in immunocompetent
mice. B16-CD20-CD46 tumor cells were implanted subcutaneously into C57BL/6 mice on day 0.
When tumors had reached average volumes of 40 mm³, animals received indicated treatments by
intratumoral injection on five consecutive days. Shown are tumor volumes over time of individual
mice in three independent experiments (A-C). mock – carrier fluid, MV – unmodified oncolytic
measles virus, MV-mCD3xCEA – virus encoding mCD3xCEA control BiTE, MV-mCD3xCD20 –
virus encoding mCD3xCD20 BiTE, pUV and cUV – virus partially and completely inactivated
by ultraviolet irradiation, respectively, mCD3xCD20 – purified vBiTE.
carrier fluid only (mock) and mCD3xCD20 vBiTE alone, respectively, tumors progressed rapidly
and the majority of mice had to be sacrificed between 10 and 20 days post tumor implantation.
Delayed tumor growth was observed following treatment with unmodified measles virus (MV)
and MV-mCD3xCEA, respectively, and most animals reached termination criteria between days
20 and 30. In the MV treatment group, a complete tumor remission was observed in one animal
(Fig. 11B). Mice treated with MV-mCD3xCD20 exhibited even more delayed tumor growth,
with no apparent differences between non-irradiated and partially (pUV) and completely (cUV)
UV-inactivated virus. While the majority of those animals did not survive more than 40 days
post tumor implantation, individual mice from each group survived more than 60 days in each of
the independent experiments, and several complete tumor remissions were observed (see 3.2.3).
3.2.2 Survival analyses
Survival was prolonged significantly for mice treated with unmodified MV and MV-mCD3xCEA,
respectively, compared to mock treatment, as assessed by Kaplan-Meier analysis of two independent
experiments (Fig. 12A and B). Median survival was 16.5 and 15 days, respectively, for the mock
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Figure 12: MV-BiTE efficacy in vivo. C57BL/6 mice bearing established subcutaneous
B16-CD20-CD46 tumors received intratumoral treatments with carrier fluid (mock) or indicated
viruses on five consecutive days. Animals were examined daily and sacrificed when termination
criteria were reached. Kaplan-Meier survival plots are shown. Statistical analysis was performed
by Mantle-Cox log-rank test with p values adjusted for multiple comparisons by Bonferroni
correction. A: n = 8 for mock; B: n = 9 for mock and MV-mCD3xCD20, respectively; n = 10 for
each other group.
groups, 25 and 24 days for MV and 23.5 and 21 days for MV encoding CEA-specific control BiTE.
Compared to those treatment groups, survival was significantly prolonged in mice treated with
MV encoding the tumor-targeting mCD3xCD20 BiTE, reaching a median of 30 days in both
experiments and resulting in one and three mice, respectively, in complete tumor remission more
than 40 days post tumor implantation.
vBiTE treatment alone had a marginal effect on survival compared to mock treatment, with a
median survival of 16 and 18 days versus 16.5 and 15 days in two experiments, respectively (Fig.
13A and B). MV-mCD3xCD20 treatment was significantly more effective than vBiTE therapy in
both experiments, while neither complete (cUV) nor partial (pUV) inhibition of virus replication
significantly impaired treatment outcome. A median survival of 30 and 29 days was observed for
MV-BiTE treatment compared to 30 and 25 days for the cUV groups, respectively (Fig. 13A
and B). pUV treatment yielded a median survival of 33 days versus 30 days for non-irradiated
MV-BiTE (Fig. 13C). Similarly, complete inactivation of unmodified MV did not significantly
abrogate efficacy in an independent experiment (Fig. 13D). Medians of survival determined
for MV cUV and MV groups were 20 and 23.5 days, respectively. This indicates that in vivo
replication is not a major determinant of therapeutic efficacy.
Regarding the presence of MV-neutralizing antibodies in the population, effects of pre-vaccination
on therapeutic efficacy was investigated. Median survival was 23.5 days in naïve mice and 25 days
in pre-immunized mice upon treatment with unmodified MV, and 21 days in naïve mice and 48
days in pre-immunized mice for MV-BiTE (Fig. 14). In the mock-treated group, median survival
was 12 days. Thus, in MV-immune mice, efficacy of intratumoral MV and MV-mCD3xCD20
treatments was not impaired compared to MV-naïve animals. One non-immunized mouse from
the MV-BiTE treatment group and three MV-immune animals, one treated with MV and two
with MV-BiTE, went into complete remission following treatment. These results indicate that
pre-vaccination did not abrogate efficacy of intratumoral virus treatment.
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Figure 13: Treatment efficacy of vBiTE and UV-inactivated viruses in vivo. C57BL/6
mice bearing established subcutaneous B16-CD20-CD46 tumors received intratumoral injections of
indicated regimens on five consecutive days: mock – carrier fluid, mCD3xCD20 – purified vBiTE
specific for murine CD3 and human CD20 antigen, MV-mCD3xCD20 – BiTE-encoding MV, cUV
– completely UV-inactivated, pUV – partially UV-inactivated. Animals were examined daily
and sacrificed when termination criteria were reached. Kaplan-Meier survival plots are shown.
Statistical analysis was performed by Mantle-Cox log-rank test with p values adjusted for multiple
comparisons by Bonferroni correction. Data shown in panels A and C were obtained from the
same experiments as displayed in Figures 12 B and A, respectively (i.e., corresponding mock and
MV-mCD3xCD20 survival curves are identical). A: n = 9 for both mock and MV-mCD3xCD20,
n = 10 for each other group; B: n = 9 for both MV-mCD3xCD20 and mCD3xCD20, n = 10 for
each other group; C: n = 8 for mock, n = 10 for each other group; D: n = 6 for each group.
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Figure 14: MV-BiTE efficacy in MV-immunized mice. B16-CD20-CD46 tumors were
implanted subcutaneously into MV-naïve C57BL/6 mice and mice previously immunized with
highly purified MV (MV-NIS) by prime-boost vaccination, i.e. two intraperitoneal injections. MV
immunity was verified by serum neutralization assay. When tumor volumes reached an average
of 40 mm³, mice received intratumoral injections of (A) unmodified MV, (B) MV encoding
mCD3xCD20 BiTE, or carrier fluid only (mock) on five consecutive days. Kaplan-Meier survival
plots are shown. Statistical analysis was performed by Mantle-Cox log-rank test with p values
adjusted for multiple comparisons by Bonferroni correction. Data of both panels were derived
from one experiment (i.e., mock survival curves are identical). vacc. – vaccinated, MV-immune
animals. n = 6 for each group.
3.2.3 Tumor re-challenge
To investigate anti-tumor immunity in C57BL/6 mice in long-term tumor remission after virus
treatment of subcutaneous B16-CD20-CD46 tumors, the animals were subjected to tumor re-
challenge by injection of 1x105 B16 cells into the contralateral flank. Mice naïve to both tumor
and MV served as implantation controls. From the survival experiments shown in Figures 12
and 13, nine animals in total had gone into complete remission and survived more than 70 days
after first tumor implantation. Six out of eight mice previously treated with MV-BiTE and the
one survivor that had received unmodified MV rejected engraftment, while all six naïve mice
developed tumors (Fig. 15, lower three bars). In a second re-challenge experiment, surviving
mice from the vaccination experiment shown in Fig. 14 were re-challenged, yielding one out of
three rejections for MV-BiTE survivors and one out of one for MV, versus no rejections by the
four naïve control mice (upper three bars). In all survival experiments performed in the course of
this study, two of 44 B16-CD20-CD46 tumor-bearing mice treated with unmodified MV showed
complete tumor remission (4.55%) and both rejected engraftment of B16 tumors upon re-challenge.
For a total of 71 animals treated with MV-mCD3xCD20, eleven complete tumor remissions were
observed (16.90%). Of these animals, seven did not develop tumors after injection with B16 cells
(63.64% of all re-challenged mice, 9.86% of all treated mice). This indicates long-term anti-tumor
immune protection in a subset of mice after tumor treatment with MV-BiTE.
3.2.4 Mechanistic analyses of MV-BiTE ex vivo
To identify mechanisms of efficacy in the B16-CD20-CD46 model, tumor-bearing C57BL/6 mice
were treated with carrier fluid only (mock), MV encoding control BiTE (MV-mCD3xCEA), or
MV-mCD3xCD20 on five consecutive days by intratumoral injection.
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Figure 15: Long-term immune protection in MV-BiTE-treated mice. In two separate
experiments, C57BL/6 mice in long-term remission after treatment of subcutaneous B16-CD20-
CD46 tumors with indicated viruses and naïve animals, respectively, were injected subcutaneously
with 1x105 B16 cells and tumor engraftment was monitored. The three lower bars display data
for re-challenge of mice from the survival experiments shown in Figs. 12 and 13 and the upper
bars show data for mice from the MV-immunization experiment (Fig. 14).
Kinetics of viral gene expression in vivo were assessed by RT-qPCR analysis of bulk RNA isolated
from tumors explanted at designated time points. mRNA levels of MV-N and mCD3xCD20 and
mCD3xCEA BiTEs, respectively, were highest for the first two measured time points, i.e. directly
after the first and the fifth intratumoral treatment (Fig. 16). While similar levels were detected
one and two days after the last treatment, values were close to baseline after five days.
To assess immunological consequences of MV-BiTE therapy, mice were sacrificed one day after
the last treatment, tumors were explanted and partitioned for cytometric and bulk RNA analyses.
The relative abundance of tumor-infiltrating lymphocyte subsets following treatment was analyzed
by flow cytometry and compared between treatment groups. A significantly increased ratio of
CD3+ cells to CD20+ tumor cells of all live cells was observed for MV-mCD3xCD20-treated mice
compared to both other groups (Fig. 17A). In addition, the ratio of CD8+ (cytotoxic) to CD4+
(helper) T cells was significantly increased (Fig. 17B). For both virus treatment groups, a trend
towards increased expression of the activation marker CD69 on CD3+ T cells was observed (Fig.
17C), whereas significantly lower levels of the inhibitory molecule CTLA-4 were detected (Fig.
17D). Compared to mock, CD4+CD25+ double positive cells were reduced among the CD3+
populations after virus treatment, although significance was reached only for MV-mCD3xCD20
(Fig. 17E). The general composition of tumor-infiltrating lymphocyte compartments indicates
induction of an effector T cell phenotype upon MV-BiTE treatment.
RT-qPCR of bulk RNA revealed a two-fold increase in Foxp3 mRNA levels after treatment with
MV-mCD3xCD20 compared to mock, while expression of Tbet mRNA was increased by factor
100 (Figure 18A). Targeted transcriptome analysis showed a significant increase in the ratio of
Cd8a versus Foxp3 expression (Fig. 18B). Compared to MV-mCD3xCEA treatment, obtained
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Figure 16: Intratumoral expression levels of viral mRNA over time. Subcutaneous
B16-CD20-CD46 tumors in C57BL/6 mice were injected with carrier fluid only (mock), MV
encoding CEA- and CD20-specific BiTE, respectively, on five consecutive days. At indicated
time points, mice from each group were sacrificed (n = 3 for MV-CD3xCEA treatment 5, n = 1
for MV-CD3xCD20 5 days after t., n = 4 for every other time point), tumors were explanted,
whole RNA was extracted and analyzed by RT-qPCR. Shown are means + standard deviation of
fold change over the average of the respective mock group. Treatment 1/5 – directly after the
first/fifth treatment, respectively; t. – treatment.
values were also higher for the MV-mCD3xCD20-treated group, with significance reached for
T-bet levels and the Cd8a/Foxp3 ratio, but not for Foxp3 expression. These data indicate a shift
from a regulatory to an effector T cell phenotype.
Targeted transcriptome analysis using a commercially available set of murine immune-related genes
(NanoString CodeSet Immunology Panel) was performed to identify treatment-induced changes
in the immune transcriptome that potentially represent determinants of therapeutic success. A
gene expression heat map was generated by agglomerative clustering including T cell activation,
differentiation, and proliferation genes pre-defined in the Advanced Analysis package of nSolver
4.0 software (Fig. 19). T cell-related genes were found to be differentially expressed in tumors
from different treatment groups. The cluster with the lowest relative expression of indicated
genes exclusively contained samples from the mock group, whereas highest relative expression was
observed for MV-mCD3xCD20-treated animals. Individual analysis further revealed upregulated
expression of genes associated with T cell inhibition and exhaustion, such as PDCD1 and CD274
which encode the immune checkpoint proteins programmed cell death protein 1 (PD-1) and
programmed death-ligand 1 (PD-L1), respectively.
3.3 Combining oncolytic measles viruses and CAR T cells
Re-direction of resting, polyclonal endogenous T cells in the context of oncolytic measles vi-
rotherapy was investigated by MV-BiTE treatment in the B16-CD20-CD46 model. Ectopic
expression of a chimeric antigen receptor (CAR) represents another method of re-direction, in
this case of ex vivo expanded and stimulated T cells, that has been approved for hematological
malignancies but lacks efficacy in solid tumors. As CAR T cell therapy has both advantages and
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Figure 17: Tumor-infiltrating lymphocytes after MV-BiTE treatment. C57BL/6 mice
bearing established subcutaneous B16-CD20-CD46 tumors received intratumoral injections of
carrier fluid only (mock), MV encoding mCD3xCEA control BiTE (MV-mCD3xCEA) or MV
encoding CD20-specific BiTE (MV-mCD3xCD20) on five consecutive days. One day after the
last treatment, tumors were explanted and single cell suspensions were prepared, stained for the
indicated markers and analyzed by flow cytometry. Populations on which gating was performed
are indicated above panels. Exemplary data from one of two independent experiments is shown.
Statistical analysis was performed by one-way ANOVA with p values adjusted for multiple
comparisons by Tukey test. ns – not significant. n = 8 for mock, n = 10 for both other groups.
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Figure 18: Expression levels of T cell transcription factors after MV-BiTE treatment.
C57BL/6 mice bearing established subcutaneous B16-CD20-CD46 tumors received intratumoral
injections of carrier fluid only (mock), MV encoding mCD3xCEA control BiTE (MV-mCD3xCEA)
or MV encoding CD20-specific BiTE (MV-mCD3xCD20) on five consecutive days. One day after
the last treatment, tumors were explanted and whole RNA was extracted. A. Expression levels
of mRNA encoding transcription factors FoxP3 and T-bet were determined by RT-qPCR and
normalized to L13A mRNA. Fold changes over the average value of the respective mock-treated
group are shown. n = 7 for mock, n = 8 for MV-mCD3xCEA, n = 10 for MV-mCD3xCD20. B.
In a separate experiment, extracted RNA was subjected to targeted transcriptome analysis and
ratios of Cd8a and Foxp3 mRNA expression levels were calculated. n = 7 for mock, n = 8 for
MV-mCD3xCEA, n = 9 for MV-mCD3xCD20. Shown are mean ± standard deviation. Statistical
analysis was performed by one-way ANOVA with p values adjusted for multiple comparisons by
Tukey test. ns – not significant.
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Figure 19: Expression levels of T cell-associated genes after MV-BiTE treatment.
C57BL/6 mice bearing established subcutaneous B16-CD20-CD46 tumors received intratumoral
injections of carrier fluid only (mock), MV encoding mCD3xCEA control BiTE (MV-mCD3xCEA)
or MV encoding CD20-specific BiTE (MV-mCD3xCD20) on five consecutive days. One day
after the last treatment, tumors were explanted and whole RNA was extracted and subjected to
targeted transcriptome analysis. Data was derived from the same experiment as shown in Figure
18B. Expression was normalized to internal reference genes and scaled for equal variance of each
gene. Color coding corresponds to indicated z-scores representing relative fold change of gene
expression. Agglomerative clustering analysis was performed for selected T cell-related genes
using nSolver 4.0 software.
49
3 Results
disadvantages compared to BiTE treatment, potential of combination with MV was investigated
for this therapeutic approach as well.
CAR vectors were provided by Dr. Daniel Abate-Daga, Department of Immunology, H. Lee
Moffitt Cancer Center and Research Institute, Tampa, FL, USA∗ Two previously published CARs
targeting prostate stem cell antigen (PSCA) as a model antigen were used in this study. The
second generation CAR, PSCA2 contains a CD28 co-stimulatory domain only, while the third
generation CAR, PSCA3, contains both CD28 and 4-1BB co-stimulatory domains158.
To achieve re-direction to PSCA-expressing cells, ex vivo stimulated human T cells were trans-
duced with CAR-encoding retroviral vectors. CAR expression was verified by flow cytometry,
reproducibly yielding high percentages of CAR-positive cells (Fig. 20A). No selection of CAR-
expressing cells was applied prior to performing experiments. Therefore, CAR-negative T cells
were still present in the CAR T cell suspension. Accordingly, numbers of untransduced human T
cells (UT) to be used as controls were always calculated according to the amount of total T cells,
not CAR T cells, present in respective samples.
The PSCA-expressing human pancreatic adenocarcinoma cell line HPAC was used as a solid tumor
model for CAR T cell therapy. As determined by flow cytometry, HPAC cells were also bound
by carcinoembryonic antigen (CEA)-specific vBiTE (Fig 20B), additionally allowing analyses of
MV-BiTE efficacy in the CAR tumor model.
The influence of designated MV and T cell combinations on HPAC cell viability over time was
determined via impedance measurement. Continuous growth over three days was observed for
untreated HPAC cells seeded on a 96-well plate (Fig. 20C, left panel). Incubation for 2 h with
MV-hCD3xCEA and MV-hCD3xCD20, respectively, at a multiplicity of infection of 1 induced
reduction in cell viability after 48 h. Addition of UT did not affect viability after 24 h but led to
reduced growth at 48 and 72 h (middle panel). When inoculated with MV encoding non-targeting
control BiTE hCD3xCD20 prior to addition of UT, growth was reduced at 24 and 48 h and no
increase in cell viability was observed at 72 h compared to the 48 h time point. When addition
of UT was preceded by inoculation with MV-hCD3xCEA, no viable cells were detected after 24
h. The same outcome was observed for incubation with PSCA2 CAR T cells, irrespective of
inoculation with virus (right panel). These results indicate effective T cell re-direction by both
approaches.
For efficacy analysis in a pilot experiment in vivo, NSG mice bearing subcutaneous HPAC
tumors received intratumoral treatment with carrier fluid only (mock), unmodified MV, or MV-
hCD3xCEA (MV-BiTE) on four consecutive days, followed by a single intravenous injection of
UT or CAR T cells and subsequent intraperitoneal application of IL-2. Tumor growth did not
differ significantly between different treatment groups (Fig. 20D). However, irrespective of T
cell application, a trend towards delayed growth upon virus treatment compared to mock was
observed. Tumor growth was also reduced upon CAR T cell treatment (right panel) compared to
without application of T cells (left) and to UT treatment (middle), respectively. Before onset
of potential graft-versus-host-disease, the experiment was terminated 34 days post treatment
initiation. Spleens were explanted from sacrificed animals and analyzed by flow cytometry. No
CD3-positive events were detected (data not shown), indicating lack of persistence of adoptively
transferred T cells in the immunodeficient hosts.
∗I learned methods of CAR T cell therapy, including isolation, expansion, transduction and application of T cells,
during a research visit to Dr. Abate-Daga’s laboratory between May 16 and August 18, 2017, in the course of
my thesis work.
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Figure 20: Combining CAR T cell and oncolytic measles virotherapy. A. Expression
of BiTE target antigen by the human pancreatic adenocarcinoma cell line HPAC. Binding of
CEA-specific vBiTE to HPAC cells was analyzed by flow cytometry using a phycoerythrin (PE)-
labeled antibody targeting the BiTE-associated HA-tag. B. Chimeric antigen receptor (CAR)
expression on human T cells. Ex vivo stimulated human T cells were transduced with a lentiviral
vector encoding prostate stem cell antigen-specific CAR of the second generation (PSCA2). Three
days after transduction, cell surface expression of CARs was analyzed via binding of protein L
conjugated to biotin, which was in turn detected using phycoerythrin (PE)-labeled streptavidin. C.
Cytotoxic potential of T cell re-direction by CARs and BiTE-encoding oncolytic measles viruses
in vitro. HPAC cells were seeded on a 96-well plate. After 24 h, adherent cells were inoculated
with medium only (no virus) or oncolytic measles viruses encoding hCD3xCEA or hCD3xCD20
BiTE at a multiplicity of infection of 1 for 2 h. Then, medium only (no T cells), untransduced,
stimulated human T cells (UT), or T cells expressing PSCA2 (CAR T) were added and cell
viability was analyzed over time via impedance measurement. Values were normalized to the
first measurement after adding T cells (normalized cell index, nCI). Shown are mean + standard
deviation of three technical replicates for each condition at indicated time points. D. CAR T and
MV-BiTE combination in vivo. Established subcutaneous HPAC tumors in immunodeficient NSG
mice received intratumoral injections of carrier fluid only (mock), unmodified MV, or MV encoding
hCD3xCEA BiTE (MV-BiTE) on four consecutive days, followed by a single intravenous injection
of carrier fluid (no T cells), untransduced, stimulated human T cells (UT), or PSCA-specific CAR
T cells (CAR T) on the next day. Recombinant human IL-2 was applied intraperitoneally for
three days to support T cell engraftment. Group means + standard deviation of tumor volumes
are shown (n = 4 for each mock group, n = 5 for each other condition).
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3.3.1 T cell labeling ex vivo
Regarding the lack of information on the fate of injected T cells in vivo, non-invasive T cell
tracking would be a useful tool to analyze homing, distribution, and persistence in individual
animals over time. To achieve detection of T cells by magnetic resonance imaging (MRI), labeling
with iron oxide nanoparticles was evaluated as a potential method. Direct incubation with
fluorophore-labeled nanoparticles alone yielded a labeling efficiency of 16.8% of live T cells
determined by flow cytometry (Fig. 21A, lower left panel). Using a previously published protocol
for nanoparticle labeling of various cell types with heparin and protamine159, labeling of more
than 75% of live cells was achieved (lower middle panel). However, protocol optimization was
necessary because high protamine concentrations were associated with increased toxicity (upper
right panel).
MRI was performed to assess labeling of T cells with the non-fluorescent nanoparticle ferumoxytol.
Dark spots indicating field inhomogeneities as induced by iron oxide nanoparticles were detected
in samples containing T cells incubated with heparin, protamine, and ferumoxytol, but not for T
cells with heparin and protamine alone (Fig. 21B). Confocal microscopy revealed presence of
fluorescently labeled nanoparticles within cells upon labeling with heparin and protamine (Fig.
21C).
3.3.2 Combining CAR T cells and MV encoding checkpoint inhibitors
While mouse survival was prolonged and a proportion of complete remissions was observed upon
MV-BiTE treatment (Figs. 12-14), there remained a potential to further increase efficacy, and an
upregulation of genes associated with T cell inhibition and exhaustion was observed (Fig. 19). To
address these issues and to further enhance the repertoire of immunomodulatory approaches for
supporting T cell re-direction immunotherapies, potential of MV-encoded checkpoint inhibitors
in CAR T cell treatment was investigated in vitro. When co-cultured with PSCA-specific
CAR T cells, an effector-to-target cell ratio-dependent reduction in viability of patient-derived
PC05 cells was observed, compared to incubation with untransduced human T cells (Fig. 22,
upper panel). CAR T cell-mediated killing was enhanced by MV encoding anti-PD-1 antibodies
Pembrolizumab (middle panel) and Nivolumab (lower panel) as compared to MV encoding control
immunoglobulin.
3.4 Mathematical modeling of T cell-based MV-immunotherapies
The complex consequences of oncolytic measles virotherapy and the availability of alternative
approaches for T cell re-direction require careful consideration of potential combination regimens.
Mathematical modeling provides a tool for exploring complex biological mechanisms at reduced
experimental cost. An appropriately designed model fitted to relevant experimental data can
support the identification of crucial therapeutic parameters and allow in silico prediction of
treatment outcomes. For a rational evaluation of the potential combinations of oncolytic measles
viruses with BiTE and CAR T cell therapies investigated in this study, a mathematical model
describing the interactions of tumor cells, oncolytic viruses, and the immune cell compartment
was therefore conceived in collaboration with Drs. Daniel Santiago and Heiko Enderling at the
Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research
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Figure 21: T cell labeling with iron oxide nanoparticles. A. Efficiency of T cell labeling
with nanoparticles ex vivo. Stimulated human T cells were incubated with fluorescein isoth-
iocyanate (FITC)-labeled iron oxide nanoparticles at 100 µg iron/mL (CLIO-FITC only), or
additionally with 20 IU/mL heparin and 30 µg/mL protamine (HPC) or 20 IU/mL heparin and
60 µgL/mL protamine (HPhighC). FITC fluorescence was analyzed by flow cytometry. B. in vitro
magnetic resonance imaging (MRI) of T cells labeled with iron oxide nanoparticles. Indicated
numbers of pre-stimulated human T cells incubated with heparin and protamine only (HP) or ad-
ditionally with ferumoxytol (HPF) were transferred to capillaries of a phantom and T2*-weighted
images were acquired. H2O and ferumoxytol diluted 1:100 in H2O served as negative and positive
controls, respectively. C. Intracellular detection of iron oxide nanoparticles. Stimulated human
T cells were incubated with heparin and protamine (HP), CLIO-FITC, or heparin, protamine
and CLIO-FITC (HPC) overnight. FITC fluorescence was analyzed by confocal microscopy. For
better visualization, contrast and brightness were equally adjusted for all presented images.
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Figure 22: Combination of CAR T cells and checkpoint antibody-encoding MV
against primary human tumor cell cultures. Human pancreatic carcinoma cells PC05
were seeded on a 96-well plate with electrodes at the bottom and incubated overnight. Carrier
fluid only (upper panel) or oncolytic measles viruses encoding control immunoglobulin G4 (MV-
IgG) or an anti-PD1 antibody, either Pembrolizumab (MV-Pembro, middle panel) or Nivolumab
(MV-Nivo, bottom panel), at a multiplicity of infection of 1 were added to the respective wells.
After 2 h of incubation, untransduced human T cells (UT) or T cells expressing a PSCA-specific
CAR of the second (PSCA2) or third generation (PSCA3) were added to indicated samples and
cell viability was analyzed over time via impedance measurement. Values were normalized to the
first measurement after adding T cells (normalized cell index, nCI). Shown are mean + standard
deviation of three technical replicates for each condition.
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Figure 23: Mathematical modeling of oncolytic measles immunovirotherapy of can-
cer. The schematic on the left visualizes a model of the interplay between uninfected (U) and
infected (I) tumor cells, (CAR) T cells (T), oncolytic virus (V), and virus-encoded immunomodu-
lators (IM) in the context of tumor immunovirotherapy. This model is represented mathematically
by the ordinary differential equations shown on the right. α – net growth rates, β – infection rate,
δ – tumor cell killing by T cells, ε – immunomodulatory enhancement of T cell cytotoxicity, ζ
–release of IM due to oncolysis of infected cells, η – death rate of infected cells, θ – release of viral
progeny upon oncolysis, κ –secretion of IM by live infected cells, λ – rates of cell death, virus and
IM degradation, respectively, ∅ – exit from the experimental system, green arrows – input by
therapeutic intervention (injection).
Institute, Tampa, FL, USA∗ (Fig. 23). The general model, which can be expanded to include e.g.
further immune cell compartments, signaling molecules, or therapeutic agents, if necessary, was
restricted to a set of ordinary differential equations describing changes of five key variables over
time.
Transfer of uninfected, i.e. virus-susceptible tumor cells (U) to an infected tumor cell compartment
(I) corresponds to the amount of virus present (V) and the attributed rate of infection (β). Death
of infected cells is associated with the release of viral progeny as well as of virus-encoded
immunomodulators (IM) such as BiTEs or checkpoint inhibitors, which in turn can affect activity
of T cells (T), resulting in reduction of both U and I. Parameters describing the respective
activities and rates of effects have to be derived experimentally. For this, in vitro and in vivo
experiments described in this thesis can inform on virus replication, infection, and cytolysis, T
cell activity and persistence, and immunomodulatory parameters of BiTEs or other MV-encoded
transgenes. Further model-guided data acquisition and subsequent fitting to the model is required
for computing outcomes of additional combination treatments and schedules in silico for future
identification of optimal conditions.
∗This collaboration was initiated and the project was conceived during my research visit to Dr. Abate-Daga’s
laboratory at Moffitt Cancer Center in 2017 in the course of my thesis work.
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Based on both pre-clinical and clinical evidence of T cell-mediated tumor regression upon oncolytic
virotherapy (reviewed in160) and shortcomings of BiTE and CAR T cell re-direction approaches
in the treatment of solid tumors in terms of safety and efficacy (reviewed in32), we proposed
a mechanism of action of combined oncolytic immunotherapy in which virus-mediated tumor
debulking and local inflammation support tumor-directed T cell responses. We furthermore
hypothesized that virus-mediated tumor-directed expression of a BiTE could achieve tumor-
restricted activity.
Attenuated measles vaccine viruses have beneficial properties for use as oncolytic agents, including
a natural oncotropism, an excellent safety profile, fusogenicity, high immunogenicity, and genetic
modifiability (reviewed in94). Therefore, to test our hypotheses, we engineered oncolytic measles
viruses encoding BiTE constructs concomitantly targeting human model tumor antigens CD20 or
carcinoembryonic antigen (CEA), respectively, and human or murine CD3 (MV-BiTE).
In this study, immune-mediated efficacy of MV-BiTE was demonstrated in a solid tumor model
in immunocompetent mice and tools to further investigate combination immunotherapies based
on MV and T cell re-direction strategies were developed.
4.1 A novel murine solid tumor model to study MV-BiTE
Due to lack of an appropriate existing mouse model to investigate efficacy and mechanism of
action of MV-BiTE in immunocompetent hosts, we had to first generate a novel syngeneic murine
solid tumor model allowing for measles virus entry and BiTE binding. In melanoma patients,
promising results were achieved by T cell-mediated immunotherapies, including adoptive cell
transfer19, checkpoint inhibition161,162, oncolytic virotherapy87,88, and oncolytic virotherapy in
combination with checkpoint inhibition91,92. For this first proof-of-concept study of MV-BiTE, we
therefore decided to use a melanoma model. The murine B16 cell line, derived from a melanoma
spontaneously formed in a wild-type C57BL/6 mouse, provides a well-established model in cancer
immunotherapy research that is characterized by low T cell infiltration and therefore especially
suited for studies on experimental therapies aiming at inducing T cell responses (reviewed in163).
B16-CD20 cells stably expressing human CD20 had been generated previously in the lab146. By
lentiviral transduction of B16-CD20 cells, we generated a B16-derived cell line expressing the
human antigens CD20 and CD46 as BiTE target and measles virus entry receptor, respectively,
for subsequent studies on MV-BiTE efficacy. While careful consideration of appropriate targets
is absolutely essential for the clinical development of novel therapeutics regarding both efficacy
and safety, we decided to use CD20 as a model antigen in this proof-of-concept study mainly
due to availability of sequences of both the antigen and an appropriate scFv164. CD20 is a
transmembrane protein expressed on most stages of B cell differentiation165 and frequently found
to be expressed on B cell malignancies166. It is the target of several approved therapeutics
including rituximab, the first approved monoclonal antibody for cancer treatment167,168. CD20
was also reported to be expressed on a subset of melanoma cells with stem cell-like properties169,
yielding promising results when targeted therapeutically in mice170 and human patients171.
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Cell surface expression of human antigens and susceptibility to measles virus were verified for
B16-CD20-CD46 cells by flow cytometry and infection experiments, respectively. Kinetics of viral
replication and virus-mediated cytotoxicity were comparable between MV-BiTE and unmodified
MV, despite insertion of a transgene of approximately 1,600 nt. Expression of human CD46 on
murine B16 cells increased titers of viral progeny by two orders of magnitude, to a similar level as
observed in Vero MV producer cells. However, progeny titers peaked later compared to Vero cells
and declined within four days, indicating post-entry restriction and limited permissiveness of mouse
cells for MV. While CD46 cell surface density may be one factor130,172, host cell-intrinsic factors
are known to limit replication of measles vaccine strain viruses in mouse cells173. Accordingly,
viral cell lysis after inoculation lagged behind on CD46-expressing B16 cells compared to Vero
cells. Without expression of human CD46, no decline in B16 cell viability was observed upon
inoculation with measles viruses.
4.2 Analyses of MV-BiTE in vitro
Importantly, we were able to isolate functional BiTEs from the supernatant of virus-infected
Vero cells, as evidenced by flow cytometry-based cell binding assay, cell-mediated cytotoxicity
assay, and target antigen-specific ELISA, which is not trivial for a negative strand RNA vector.
Binding of BiTEs to target cells was antigen-specific. Observed percentages of peripheral blood
mononuclear cells (PBMCs) bound by BiTEs specific for CD3 and CD20 correspond to literature
values of relative T and B cell levels, respectively174. Target antigen-specific, BiTE concentration-
dependent lysis of tumor cells by immune effector cells in vitro was demonstrated by lactate
dehydrogenase assay. Compared to human PBMCs, a longer co-incubation time and higher BiTE
concentrations were required for murine T cells and lower overall values of relative specific lysis
were observed, indicating limitations of this assay for primary mouse immune cells. Despite
sub-optimal culture conditions yielding relatively high background LDH release by murine T
cells, BiTE-mediated target cell lysis was demonstrated for three independently produced BiTE
suspensions. Thus, specificity and functionality of BiTEs expressed by virus-infected cells was
shown in vitro.
Production of good manufacturing practice (GMP)-grade MV is possible in bioreactors95, but
not routinely performed in the academic setting. Therefore, virus suspensions were produced
from crude lysates of infected cells, resulting in the presence of cellular proteins and BiTEs at
relatively high levels of approximately 2 µg/mL, as estimated by protein analyses150. While this
allows for introduction of MV-encoded BiTEs into murine tumors without having to rely entirely
on de novo synthesis of the transgene by mouse cells, it represents a crucial limitation for animal
experiments which required careful consideration of appropriate controls.
4.3 MV-BiTE efficacy in immunocompetent mice
B16-CD20-CD46 cells engrafted in immunocompetent C57BL/6 mice and formed subcutaneous
tumors at the site of injection despite the expression of foreign antigens. This model was used
to investigate efficacy of MV-BiTE following the established schedule of five intratumoral virus
injections on consecutive days146.
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Intratumoral treatment with suspensions of unmodified MV and MV encoding a control BiTE,
both also produced from crude cell lysates and thus of similar composition as MV-BiTE, prolonged
survival of mice bearing subcutaneous B16-CD20-CD46 tumors compared to mock treatment, but
were significantly less effective than MV encoding BiTEs specific for the tumor target antigen
CD20. This was not due simply to the injection of CD20-targeting BiTE molecules present in the
virus suspension, as intratumoral injection of an equivalent amount of purified BiTE alone had
little effect. The analysis of viral gene expression kinetics revealed a decrease in BiTE and MV-N
mRNA levels to baseline within five days after treatment. Moreover, previous UV irradiation of
MV-BiTE and unmodified MV to decrease replicative capacity did not abrogate efficacy of either
treatment, indicating that viral replication in vivo was not a main driver of anti-tumor efficacy
in this model. However, UV irradiation may have influenced not only viral replication, but also
the molecular composition of the virus suspension, potentially leading to higher immunogenicity
e.g. via danger-associated molecular patterns. For the murine paramyxovirus Sendai, anti-tumor
efficacy after UV inactivation was observed and shown to rely on an interferon response induced
upon recognition of disrupted viral RNA via intracellular retinoic acid inducible gene I (RIG-I)
(reviewed in175). In addition, for an oncolytic vaccinia virus, inactivation of viral gene expression
and replication increases immune-mediated anti-tumor efficacy176. As this depends on inactivation
of a gene involved in preventing antiviral host cell responses to sensing of viral DNA, the same
mechanism cannot account for RNA viruses such as MV. Still, although highly speculative, a
similar mechanism may have masked a decrease in anti-tumor efficacy based on reduced lytic
replication of irradiated MV. Nevertheless, our findings indicate that non-replicating MV-BiTE
can induce durable tumor remissions, providing a potential approach to increase safety of oncolytic
virotherapy. Furthermore, in a more permissive tumor, increased lytic replication may facilitate
enhanced therapeutic efficacy of MV-BiTE as compared to the B16-CD20-CD46 model.
In immunodeficient NSG mice bearing subcutaneous CEA-expressing human colorectal carcinoma
tissue sphere culture xenografts, intratumoral injections of MV encoding a CEA-targeting BiTE
in combination with transfer of unstimulated human PBMCs resulted in prolonged survival,
compared to both monotherapies alone150,151. High levels of sustained viral gene expression were
observed in virus-treated tumors. Although MV-BiTE efficacy in both models cannot be directly
compared, this provides evidence for enhanced virus replication in a more permissive model,
associated with anti-tumor activity of transferred PBMCs. Importantly, in this model that allows
for expression of high BiTE levels, no BiTE was detected in peripheral blood. However, MV-BiTE
pharmacodynamics and potential toxicities would need to be analyzed in more relevant models
prior to future clinical development. Transgenic mice expressing human CD46 in all nucleated
cells in a similar pattern as in humans are available for biodistribution studies and can also be
used for efficacy analyses, and toxicity studies are often performed in macaques, which more
closely mimic the human organism93,177.
Efficacy of MV encoding anti-CEA BiTE was furthermore assessed in C57BL/6 mice bearing
subcutaneous murine colon carcinoma MC38-CEA tumors stably expressing human CEA as a
BiTE target antigen150,151. Notably, MC38-CEA cells lack expression of an MV entry receptor
and thus are less susceptible to MV infection than B16-CD20-CD46 cells. MC38-CEA-CD46
cells expressing human CD46 were generated analogously to B16-CD20-CD46, but ulcerated
quickly when injected subcutaneously into C57BL/6 mice and were frequently rejected. Due to
the origin from a murine colon carcinoma induced by chemical carcinogens178, parental MC38
cells have a high mutational load179 and tumors show high baseline levels of T cell infiltration.
A previous study reporting loss of MC38 tumorigenicity after transduction with a retroviral
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vector encoding murine IL-12 indicates potential for T cell-mediated rejection upon expression
of foreign genes180. In a subcutaneous MC38 model, previous work in our lab has shown high
rates of T cell-mediated complete tumor remissions following treatment with an IL-12-encoding
MV181. Therefore, also without exogenous expression of IL-12, expression of two foreign antigens
may tip the balance of tumor immunosurveillance in C57BL/6 mice in favor of anti-tumor T
cell responses and thus facilitate rejection of MC38-CEA-CD46 tumors. Therefore, MC38-CEA
cells not expressing human CD46 were used. Interestingly, treatment with both MV encoding a
CEA-targeting BiTE or a CD20-targeting control BiTE, respectively, induced high rates of tumor
remission in this model, indicating that in this immunologically “hot” tumor model, neither viral
replication nor specific BiTE activity were required for inducing anti-tumor immunity. This adds
to the conclusion that viral replication is not necessarily required for anti-tumor efficacy and that
immune-mediated mechanisms of action dominate in the models studied.
Previous studies with immunocompetent C57BL/6 mice have been performed in the lab using
MV re-targeted to human CEA or CD20 ectopically expressed on the surface of MC38 or B16
cells, respectively. In the MC38-CEA model, MV encoding GM-CSF yielded promising results
compared to control viruses, including delayed tumor growth, prolonged overall survival, complete
tumor remissions, and long-term immune protection143. However, this approach was not successful
in the B16 model. MV encoding checkpoint inhibitors showed prolonged overall survival in the
B16-CD20 model, but no durable complete tumor remissions were observed146. T cell infiltration
into B16 tumors was still limited upon combination treatment with MV and checkpoint inhibition,
indicating that an alternative strategy aiming at inducing activation and proliferation of T cells,
such as BiTE-mediated re-direction, could achieve improved treatment outcome.
With regards to the high prevalence of measles immunity in the general population, we analyzed
the impact of MV-immunization on treatment outcome in the B16-CD20-CD46 model. To this
end, we pre-immunized C57BL/6 mice with highly purified MV-NIS. Immunization was confirmed
via ex vivo serum neutralization assay. This did not result in reduced efficacy of treatment
with MV-BiTE and unmodified MV, respectively, compared to MV-naïve mice, which may be
attributed at least in part to the intratumoral route of administration. This has translational
implications as these results indicate that MV-immune individuals may still benefit from MV-
BiTE treatment despite the presence of neutralizing antibodies in serum, but this requires further
investigations. Interestingly, a recent study demonstrated increased efficacy of oncolytic reovirus
in presence of neutralizing antibodies via a monocyte-dependent mechanism182. This challenged
the former paradigm of neutralizing antibodies being a hindrance to oncolytic virotherapy,
which had led to the development of several approaches to achieve antibody escape, including
immunosuppressive pre-conditioning183, virus shielding184, usage of cell carriers185-190, mutation
of known antibody epitopes85, and envelope exchange85,155,191-193. We observed a statistically
non-significant trend towards prolonged survival and increased occurrence of complete tumor
remissions in MV-immunized versus naïve mice. Based on these observations, a new project was
initiated in the lab in which we are investigating potential roles of neutralizing antibodies and
immune cells such as monocytes in the delivery of MV as evidenced for oncolytic reovirus.
Considering the observed median survival of mock-treated mice of below 20 days, the subcutaneous
B16-CD20-CD46 tumor model is fairly aggressive. Nevertheless, in approximately 5% and 17%
of all C57BL/6 mice treated with unmodified MV and MV-BiTE in the course of this study,
respectively, complete tumor remissions were observed. Re-challenge experiments with parental
B16 cells not expressing the foreign antigens CD20 and CD46 demonstrated long-term systemic
immune protection in a subset of these animals. Importantly, this furthermore indicated immune
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responses against endogenous B16 antigens upon MV-BiTE treatment and thus antigen spread,
supporting our initial hypothesis of achieving anti-tumor protection by combining T cell re-
targeting and antigen-agnostic vaccination by MV.
4.4 Mechanisms of action of MV-BiTE
Long-term immune control implies a T cell-mediated mechanism of action. Therefore, we analyzed
tumor-infiltrating lymphocytes by flow cytometry. Upon MV-BiTE treatment, increased T cell
infiltration into the tumor and high CD8+ to CD4+ T cell ratios were observed, indicating a
strong cytotoxic T cell response. T cells were activated by treatment with both MV-BiTE and MV
encoding a control BiTE, respectively, as evidenced by a trend towards higher proportions of T
cells expressing the activation marker CD69. Relative abundances of Tregs and of T cells positive
for the co-inhibitory molecule CTLA-4 were reduced upon MV-BiTE treatment, and a TH1-skewed
pro-inflammatory cytokine response was indicated by 100-fold upregulation of the transcription
factor T-bet194. NanoString targeted transcriptome analysis revealed strong clustering of different
treatment groups according to relative expression of T cell-related genes, with MV-BiTE treatment
yielding highest expression levels. This included not only genes associated with T cell activation,
differentiation, and proliferation, but also with T cell inhibition and exhaustion. Although the
proportion of CD3+ T cells expressing CTLA-4 was reduced according to flow cytometry data,
overall expression levels of Ctla-4 were elevated compared to mock treatment, which may be
explained by the increase in absolute numbers of tumor-infiltrating T cells. These data provide
a rationale for future combination with checkpoint blockade antibodies, which might further
prolong survival and increase incidence of complete tumor remissions compared to MV-BiTE
treatment alone.
Furthermore, the data represent a resource for exploratory rather than simply descriptive analyses,
yielding several target genes which may be associated with efficacy, including CXCL9 and CXCL10,
among others. Validation of these targets and investigation of potential mechanisms is the aim
of another recently started research project in the lab. However, so far only a correlation of T
cell responses and MV-BiTE efficacy was demonstrated, and efficacy and mechanistic analyses
were not performed in the same animals. To validate a causative connection between observed
T cell responses and efficacy, depletion experiments will be performed in the future. For this,
mice will receive antibodies targeting individual subpopulations of immune cells, including
CD8+ T cells, CD4+ T cells, and natural killer (NK) cells, respectively, prior to tumor cell
implantation and throughout the experiment. In addition, the role of dendricitc cells (DCs)
may be evaluated in BatF3-knockout mice195,196, and macrophage depletion can be achieved
by injection of liposomes containing clodronate197,198. In these settings, MV-BiTE treatment
will be compared to unmodified MV and mock treatment, respectively, to evaluate the relative
contributions of these cell types to efficacy. Based on the present data, we hypothesize that
efficacy will rely mainly on CD8+ T cells via direct BiTE-mediated and TCR-specific cytotoxicity,
but to smaller degree also on CD4+ T cells via cytokine release and BiTE-mediated induction of
apoptosis in tumor cells and possibly on DCs via T cell priming.
Regarding the characteristics of the T cell response upon MV-BiTE treatment, T cell receptor
sequencing, together with cloning of identified TCRs and antigen stimulation assays, can provide
insights into the clonality and specificity of the T cell compartment199. With this method, we
aim to address various questions, including whether known B16 antigens might play a role in
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tumor recognition. We propose that several clones, rather than one single clone, drive anti-tumor
efficacy due to MV-induced antigen spread. Presence or absence of clones with a particular
specificity might be decisive for treatment success. Furthermore, studies showed that CAR T
cells with original specificity for viral antigens are especially effective in mediating anti-tumor
responses200-202. We therefore hypothesize that virus-specific T cells re-directed by BiTEs may
have added to the efficacy observed in pre-immunized mice.
Oncolytic viruses are a unique class of novel immunotherapeutics especially suited for combination
therapies203-206. Similar to our approach, other researchers have proposed207-210 and investigated
combinations of oncolytic viruses with tumor-targeting BiTEs211-213 or CARs214-218 or both
BiTEs and CARs219. Anti-tumor efficacy of the mentioned combinations was observed in various
solid tumor models. Yu and colleagues were the first to test a BiTE-encoding oncolytic virus
in vivo. In xenograft experiments in immunodeficient mice with intratumoral PBMCs, they
reported anti-tumor efficacy of a vaccinia virus encoding an anti-EphA2 BiTE211,220. Oncolytic
adenoviruses encoding BiTEs targeting EGFR212 and EpCAM213, respectively, showed efficacy
in an immunodeficient mouse model with transfer of immune cells and in cancer biopsies ex
vivo, respectively. Wing et al. used the anti-EGFR BiTE-encoding adenovirus in combination
with folate receptor alpha (FRα)-targeted CAR T cells, showing BiTE-mediated CAR T cell
re-direction in vitro and increased anti-tumor efficacy compared to the respective monotherapies
in immunodeficient mice219. Further studies used oncolytic viruses as a vector for tumor-targeted
delivery of immunotherapeutic transgenes, including chemokines218, checkpoint inhibitors215, or
both cytokines and checkpoint inhibitors214, to support CAR T cell efficacy in immunodeficient
models. Additionally, the use of CAR T cells as carriers for oncolytic viruses has shown
promising results in vitro221. Recently, two groups have reported anti-tumor properties of
oncolytic adenoviruses encoding a BiTE targeting cancer-associated fibroblasts222,223, thereby
expanding the repertoire of potential targets beyond tumor cells alone.
This multitude of recent studies illustrates the current interest in such combination approaches
and the versatility of the field. In one recent study, efficacy of combination treatment with
murine mesothelin-targeted CAR T cells and an oncolytic adenovirus encoding the cytokines
TNFα and IL-2 was observed in a syngeneic mouse model of pancreatic ductal adenocarcinoma216.
However, to our knowledge, no other study has yet shown efficacy of combining oncolytic viruses
and T cell re-direction immunotherapies in an organism with an intact immune system, i.e. an
immunocompetent mouse model. Rather, experiments were performed in immunodeficient mice,
which is a highly artificial model that additionally has limitations regarding lack of cytokines
and thus T cell homing and persistence, and in patient-derived ascites fluids containing a
clinically relevant composition of human tumor and immune cells and cytokines but lacking
three-dimensional structures of a solid tumor, associated vasculature and lymphoid organs, and
organismic compartmentalization in general. In the present study, we provide evidence for efficacy
of a BiTE-encoding oncolytic virus in an immunocompetent model for the first time.
4.5 Combining oncolytic measles virotherapy with CAR T cells
CAR T cells as a defined effector cell population can serve as a simplified model to investigate
the impact of oncolytic viruses on T cell distribution, activity, and persistence in vivo. For
combination experiments with oncolytic measles viruses, we used an established model of CAR
T cell therapy of pancreatic carcinoma. Patients diagnosed with pancreatic carcinoma have a
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median overall survival of only approximately six months, also because diagnosis often occurs at a
late stage of the disease when tumors progress rapidly224. Limited treatment options are available,
especially by immunotherapeutic approaches, due to dense stroma and strong immunosuppression.
CAR constructs targeting prostate stem cell antigen (PSCA) have been shown to be effective in a
mouse xenograft model of pancreatic cancer158. However, PSCA expression on normal tissues
prevents direct translation to clinical application due to potentially severe on-target off-tumor
effects225. Therefore, novel approaches are desperately needed for safe and effective treatment of
pancreatic carcinoma, with combination of CAR T cell therapy with oncolytic virotherapy as one
strategy.
Identification of highly specific target antigens such as claudin 18.2 in gastric and pancreatic
cancer226-230 represents a potential way to achieve efficient targeting at relatively low risk of side
effects. Targeting of several target antigens by different components of a combination treatment
regimen can promote higher specificity and thus increased efficacy without compromising safety.
Several approaches have been reported of multi-specific antibody (reviewed in231,232) and CAR
constructs233,234, respectively, to address both intra-patient and inter-patient heterogeneities.
Trivalent CAR T cells targeting HER2, IL13Rα2, and EphA2 were effective against glioblastoma
xenografts in immunodeficient mice233, and CAR T cells simultaneously targeting CD19, CD20,
and CD22 showed tumor cell killing in patient-derived B-ALL cells in vitro234. Further studies
investigated the use of modular CARs to decouple cytotoxic potential and antigen specificity235-238.
The UniCAR platform uses T cells expressing a CAR lacking a targeting moiety and target-
ing modules binding to the inert CAR T cells for re-direction. This allows for simultaneous
targeting and for switching CAR specificity during treatment and might potentially benefit
from a combination with tumor-restricted expression of targeting modules by oncolytic viruses.
Reported UniCAR-targeted antigens tested in immunodeficient mouse models include CD33 and
CD123 in an acute myeloid leukemia (AML) model238, CD19 in a B-ALL model235, and EGFR
in epithelial cancer models236,237. The potential of modulating specificity on various levels via
pre- and post-entry targeting of MV and additionally choosing appropriate BiTE and/or CAR
targets provides flexibility to the combination platform investigated in this study. Antigen escape
frequently occurs in the treatment of CD19-positive hematological malignancies by BiTEs and
CARs, causing relapses. While targeting several antigens concomitantly may help to overcome
this limitation of antigen-specific treatments, importantly, MV-mediated immune activation and
antigen-agnostic vaccination as described above may represent another strategy to effectively
prevent antigen escape.
HPAC cells provided an ideal model target for testing both CAR- and BiTE-mediated T cell re-
direction as well as measles virus-induced oncolysis due to simultaneous expression of PSCA, CEA,
and CD46 surface antigens. Both targeting of PSCA by CARs and of CEA by MV-encoded BiTEs
achieved rapid eradication of tumor cells in vitro within one day, while virus-mediated cytotoxicity
was observed after two days. Nevertherless, a pilot experiment in NSG mice bearing subcutaneous
tumors did not result in statistically significant differences between tested monotherapies and
combination treatments. Although this might be due to small group sizes resulting in low
statistical power of this experiment, treatment dosing and scheduling were probably not optimal.
MV treatment on four consecutive days was followed by T cell injection according to the standard
protocols. A suboptimal T cell dose of 10% of the dose known to be curative in the model158
was intentionally chosen to be able to observe a possible benefit of additional MV treatment.
Combination with checkpoint inhibition may improve efficacy, as observed in a co-culture assay
with PSCA-specific CAR T cells and patient-derived human pancreatic tumor cells in vitro. Tumor
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cells lysis by CAR T cells depended on the effector-to-target cell ratio and was accelerated when
tumor cells had previously been inoculated with MV encoding checkpoint inhibitors, compared
to MV encoding control IgG. A higher initial T cell number might also improve outcome in the
NSG, as no T cells persisted 30 days post injection. For future experiments, we tested T cell
labeling with iron oxide nanoparticles for detection by MRI, as non-invasive longitudinal tracking
would provide a useful tool to monitor T cells in vivo. High labeling efficiencies were achieved
and labeled T cells were detected via MRI in vitro. In future experiments, immunohistochemistry
will be performed on labeled T cells to identify nanoparticle distribution, and viability and
functionality of labeled T cells will be assessed in vitro. Subsequently, detection of T cells labeled
with iron oxide nanoparticles by magnetic resonance imaging will be assessed in vivo, comparing
different injection routes and T cell doses. These data can be used for treatment optimization.
4.6 Mathematical modeling
Exhaustive testing of alternative treatment schedules to identify a potentially successful experi-
mental layout in terms of order and dosing of treatments would not have been feasible. Although
the complex dynamics of combination immunotherapy and oncolytic virotherapy are drastically
simplified and “all models are wrong by definition”239, mathematical models provide the possibility
to identify crucial treatment parameters and generate novel hypotheses (reviewed in240,241). A
previously published mathematical model describing oncolytic virotherapy in combination with
immune checkpoint inhibition, for example, indicates an optimal dose of an immune checkpoint
inhibitor that, if exceeded, results in reduced anti-tumor efficacy due to enhanced anti-viral
immune responses242. The authors concluded that such levels of checkpoint inhibition should
be avoided in clinical trials, indicating the potential of mathematical modeling for translational
research. Other models have been developed to analyze combinations of oncolytic viruses with
radiotherapy243, a proteasome inhibitor244, or transfer of dendritic cells245, among others.
To cope with the multitude of potential treatment combinations and to be able to optimize
treatment schedules without exhaustive empirical testing, a mathematical model of MV and T cell
combination treatments was conceived in this study and will be further developed in the future
following a general approach to mathematical modeling of oncolytic virotherapy246. As a next
step, the model needs to be calibrated by fitting to experimental data. Results from this thesis
will be used and additional parameters will be derived by appropriate experiments, if necessary.
Subsequently, validation of the model will be performed by predicting experimental outcomes
and comparing these to experimentally derived results. If necessary, the complexity of the model
can be increased or reduced. For example, additional immune cell compartments can be added or
the parameter describing virus replication might be removed. Finally, in silico studies will be
performed to provide new insights and guide rational development of treatment regimens.
4.7 Conclusion and outlook
The present thesis provides, for the first time, proof-of-concept for combination immunotherapy
with a BiTE-encoding oncolytic virus in an immunocompetent mouse model. Our data furthermore
provide a rationale for future combination of MV-BiTE therapy with immune checkpoint inhibition.
A model for simultaneous targeting of distinct tumor surface antigens by MV, BiTEs, and CARs
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was established and pilot experiments in vitro and in immunodeficient mice indicated functionality
of tumor targeting. Furthermore, CAR T cell activity against pancreatic tumor cultures was
increased by MV-encoded checkpoint inhibitors. Finally, we established a protocol for T cell
labeling with iron oxide nanoparticles for future in vivo tracking via magnetic resonance imaging
and a mathematical model to perform in silico studies to predict outcome of experimental
combination treatment schedules.
In the future, immune cell depletion experiments will be performed in the B16-CD20-CD46
model to evaluate the relative contributions of distinct immune cell subsets to MV-BiTE efficacy.
Furthermore, TCR sequencing will be applied to analyze clonality of tumor-reactive T cells. Based
on targeted transcriptome analysis data, combination treatment with checkpoint inhibition will be
performed to further improve efficacy of MV-BiTE in this model. Nanoparticle uptake by T cells
will be validated by immunohistochemistry and viability and functionality of labeled T cells will
be evaluated prior to assessing MRI-based detection in vivo. For calibration of the mathematical
model, relevant parameters will be derived at required resolutions and model predictions will
be validated experimentally before applying the model for hypothesis generation and treatment
schedule optimization. This will support future development of combined oncolytic measles virus
and T cell re-direction therapies to hopefully provide improved treatment options to cancer
patients.
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